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1
CHAPTER 1 – INTRODUCTION
1.1. Antibacterial resistance
Since the discovery of penicillin over 70 years ago,1-2 many antibiotics have been
developed. Antibiotics have improved public health and human well-being, which has
also led to widespread overuse.3 Some commonly used antibiotics and their class
designations are listed in Table 1.1. There are antibiotics that target cell wall synthesis
(e.g., penicillins),1-2 folate synthesis (e.g., sulfonamides),4 DNA topoisomerases or DNA
gyrases

(e.g.,

fluoroquinolones),5

and

protein

synthesis

(e.g.,

tetracyclines,6-7

macrolides,8 and aminoglycosides9-12). Structures of some antibiotics from each class
are shown in Figure 1.1. Many drugs that target protein synthesis inhibit the elongation
step,3 but numerous modes of action exist. Some mechanisms involving the bacterial
ribosome include binding to the 30S subunit10-11,
disrupting translocation8,

15

13-14

and inhibiting tRNA binding,6 or

and tRNA recognition by interacting with the peptidyl

transferase center (PTC) or the decoding region (A site).15 Macrolides, lincosamides,
and streptogramin A (MLS) are known to target the PTC region of the 50S subunit and
block the peptide exit tunnel.8,

15-16

Aminoglycosides are known to interact with the

decoding region of the 30S subunit and interfere with tRNA selection.10-11, 14, 17

Table 1.1. Major antibiotic classes, examples, and their targets
classes

examples

target

penicillins1-2

penicillin, amoxicillin

peptidoglycan cell wall synthesis

tetracyclines6-7

tetracycline, doxycycline

A site of 30S subunit

macrolides8

azithromycin, erythromycin

peptide exit tunnel

aminoglycosides9-12

neomycin, kanamycin,
paromomomycin

A site of 30S subunit

sulfonamides4

prontosil, sulfafurazole

dihydroopteroate synthetase

fluoroquinolones5

ciprofloxacin, levofloxacin

DNA topoisomerase, DNA gyrase

2

Figure 1.1. Structures of antibiotics from each class are shown.

Although antibiotics have helped decrease the number of deaths in the world,
antibacterial resistance has emerged due to overuse. According to the U.S. Center for
Disease Control & Prevention (CDC), antibacterial resistance causes 23,000 deaths per
year in the U.S. Along with C. difficile and N. gonorrhoeae, ESKAPE (E. faecium, S.
aureus, K. psneumoniae, A. baumannii, P. aueruginosa, and E. coli) defines the list of
antibacterial resistance threats.18-19 The antibiotic targets and resistance mechanisms
are summarized in Figure 1.2.7-8, 14 The mechanism of action for antibiotics generally
relies on interacting with a given target and altering its structure and/or function. The
locations are indicated in Figure 1.2. Organisms have found ways to avoid these
mechanisms, leading to drug resistance. The resistance mechanisms fall into four

3
general categories: efflux, target modification, drug modification by enzymes, and target
enzyme inactivation.20-22 It can be noted that the mode of action is usually through one
type of mechanism, while the resistance happens in more than one type of mechanism
(Figure 1.2). Understanding these resistance mechanisms is critical for the development
of new classes of drugs.

Figure 1.2. The locations of antibiotic targets and the resistance mechanisms are
summarized, along with examples of drugs in each category.7-8, 14-15 Modes of action are
labeled on the left side of the figure. Most of the known antibiotics have developed
resistance through four main mechanisms, which are listed on the right.

Aminoglycosides are widely used drugs that have been subject to multiple routes of
resistance.13-14,
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Aminoglycosides contain 2-deoxystreptamine (2-DOS) moieties that

are highly charged (Figure 1.3), and bind to many RNAs through electrostatic
interactions.9,

14

The 2-DOS moiety is proposed to stabilize a specific conformational

state of A1492 and A1493 in the 30S subunit that results in miscoding.23 The amino
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groups are positively charged under physiological conditions, which make the
aminoglycosides overall highly charged. Aminoglycosides face resistance mainly due to
modification on their amino or hydroxyl groups.10, 17, 24 For that reason, they have been
modified by addition of different moieties, simplification of their structures, or the
formation of hybrid structures, in helping protect them from further modification by
resistance enzymes and/or to improve their binding to the RNA target.25-26

Figure 1.3. Structures of two representative aminoglycosides that contain the 2-DOS
moiety are shown. The 2-DOS moiety highlighted in red, which is an important scaffold
for RNA binding, is highly conserved among this class of antibiotics.

Although drug resistance is increasing, approval and discovery of new compounds is
decreasing.27-28 The reason for this decline in drug discovery is due to high costs and low
profitability because of inherent resistance of naturally derived compounds. 29 To
overcome this problem, new approaches are needed such as discovery of new targets
or development of new classes of compounds to target bacteria.3 In this thesis work, my
goal was to catch two birds with one stone by studying a new target, helix 69 (H69) of
23S rRNA of the bacterial ribosome that is known to play important functional roles,30-33
and by using phage display to identify a new class of peptide molecules to target H69.
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1.2. Helix 69 of the 50S ribosome subunit
1.2.1. Structure of helix 69
Helix 69 (H69) is a 19-nucleotide (nt) motif residing in 23S ribosomal RNA (rRNA) of
the

50S

subunit

in

bacterial

ribosomes.33

The

sequence

of

H69

is

5′-

GGCCGΨAACm3ΨAΨAACGGUC-3′, in which A, G, C, U, Ψ, and m3Ψ are adenosine,
guanosine, cytidine, uridine, pseudouridine, and 3-methylpseudouridine, respectively
(Figure 1.4).34-35 Pseudouridinylation is the most commonly occurring modification of the
nucleoside, in which the uracil base is detached from the ribose by an enzyme called
RluD, rotated by 120°, then reattached to the sugar.36-39 The glycosidic linkage becomes
a C-C bond, and through the isomerization reaction, an extra imino group becomes
available for hydrogen bonding.40 Three Ψs are observed in H69, with methylation at
Ψ1915.33-34, 41

Figure 1.4. The structures of the nucleosides found in H69 are shown.
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The sequence and structure of H69 are conserved throughout phylogeny, and the H69
motif is also observed in humans (Figure 1.5).34,

41-42

In human H69, five Ψs are

observed, and unlike E. coli, methylation does not occur at Ψ3731.34 Previous NMR
studies showed that the Ψs stabilize RNA due to increased base stacking,43-44 while the
individual nucleoside modification destabilizes the overall H69 structure.45 The
secondary structure of H69 is reported to be a hairpin loop, in which residues G1906Ψ1911 form hydrogen bonds to residues A1919-C1924 to stabilize the hairpin structure,
and A1912-A1918 form the loop.46 In human H69, there is a G at position 3734, whereas
E. coli H69 contains an A at the corresponding 1918 position.47 There is a G1907-U1923
wobble base pair in the stem.46 There is also a reverse-Hoogsteen base pair at A1912Ψ1917 in the wild-type (WT) and ΨΨΨ variants, which was suggested to stabilize H69
structure.48-49

Figure 1.5. The sequences and secondary structures of H69 synthetic variants are
shown. Variations include: a) E. coli WT H69, b) E. coli modified H69 ΨΨΨ, c) E. coli
unmodified H69 UUU, and d) human H69.

1.2.2. Post-transcriptional modifications in the ribosome
Post-transcriptional modifications, such as Ψ, observed in rRNA, are proposed to play
roles in regulation of the functions of rRNA by altering binding interactions or ligand
recognition.48, 50-51 Modifications can occur by breaking the glycosidic bond or altering the
bases in either a simple or complex manner (Figure 1.6). More specifically, there are
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four major types of modifications: isomerizations, methylations of the base, methylations
of the sugar (2’-OH), and multiple modifications.48, 52

Figure 1.6. Nucleoside structures and examples of the four major types of
modifications: isomerization, methylation of the base, methylation of the sugar, and
multiple modifications are shown in pars a-d, respectively.

To date, 36 modified nucleosides have been reported to occur in E. coli ribosomes in
the PTC and A site, regions essential for translation.50, 52-53 This correlation implies a
functional significance of the modified nucleosides for translation. Modifications of the
rRNA can result in altered interactions with other RNAs, proteins, or cofactors, likely finetuning the ribosome structure and function during translation.32, 54 Modifications of the
rRNA will affect direct contacts, stacking, or base-pairing interactions, thus stabilizing or
sometimes destabilizing the complex.48, 50 Therefore, rRNA modifications are factors that
cannot be overlooked in antibiotic development studies.
1.2.3. Function of helix 69
Helix 69 comprises the intersubunit bridge B2a, where the 50S and 30S subunits
interact to form the complete 70S ribosome (Figure 1.7).46, 55-56 The interaction is mainly
between those two subunits with helix 44 (h44) of the 30S subunit, in which A1913 of
H69 moves into a pocket formed by h44 and contacts the ribose of the A-site tRNA.57-58
Residue A1912 also interacts with C1407 and G1494 of h44, and A1919 interacts with
U1495.46, 49, 59 The loop region of H69 interacts with tRNA, which is important for tRNA
selection and can lead to miscoding when mutations take place.59-60 Crystal structures
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have also shown that residues in the stem region, namely G1921 and G1922, interact
with the D stem of the P-site tRNA.46, 58 It was also reported that H69 interacts with
release factors (RF1 and RF2) at C1914 and the ribosome recycling factor (RRF) at
Ψ1915 and A1916, which indicates the multiple roles of H69 in translation.61-63
Ribosomes lacking Ψ have been reported to cause slower growth rates of E. coli and
have reduced subunit association in vitro, with a corresponding loss in fidelity and
translation termination.30, 64

Figure 1.7. The location of H69 in the ribosome is shown. The figure is a cartoon
representation of the PDB structure 4V50 with h44 and H69 of bridge B2a in spacefilling mode.65

1.2.4. The conformational change of helix 69
As mentioned in the previous section, H69 is located in the B2a intersubunit bridge.46,
55-56, 63

Helix 69 undergoes a conformational change involving A1913 in the loop as it

makes direct contacts with A1493 in h44 during ribosome assembly.32 Residue A1493 of
h44 plays important roles in decoding; thus, certain modifications or mutations in the
interacting H69 loop region will affect translation. H69 can be induced to undergo
conformational changes with differing solution conditions, such as altered pH or Mg2+

9
concentrations.66-67 At low pH values (~5.5) and low Mg2+ concentrations (0 to 5 mM),
residue A1913 of H69 displays a stacked-in conformation. In contrast at higher pH
values (~7.5) and increased Mg2+ concentrations (6 to 10 mM), the same nucleotide flips
out and becomes more exposed to solvent.67 These conformations are referred to as
“closed” and “open”, respectively (Figure 1.8). Higher Mg2+ concentrations induce more
changes with modified H69 (ΨΨΨ), when compared to the corresponding unmodified
H69 (UUU).67 These changes were observed in solution and in X-ray structures with full
ribosomes as well as the model systems.66-68 Based on these structural changes, which
were observed in crystal structures of 50S (closed)55 and 70S (open)69 ribosomes, pH- or
salt-dependent studies were performed on H69 in this study.

Figure 1.8. Two different conformational states of H69 are shown. The H69 domain
from X-ray crystal structure of either 70S (open)69 or 50S (closed)55 ribosomes is
shown.

1.3. Peptides as drugs
1.3.1. General information on peptide drugs
Peptides have been used as drugs for more than 70 years,70 and have been promoted
in the field since Merrifield developed solid-phase peptide synthesis.71 Traditional
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peptides such as oxytocin, insulin, and cyclosporine are still commonly used. There are
also newer peptide drugs developed commercially in use.70,

72

Lantus developed by

Sanofi-Aventis, also known as insulin glargine (an insulin analogue that helps control
sugar level of diabetic patients), was one of the top ten biological drugs sold in 2013.73
Its structure is very similar to insulin, except that the asparagine residue at position 21
was replaced with glycine, and two arginines were added to the C-terminus. The
arginines raise the pI of the peptide, causing it to aggregate under physiological
conditions such that release into the bloodstream is slowed down.73-74
Peptides are desirable drug candidates because of low toxicity, high diversity of
sequences, lower immunogenicity, and high specificity for their targets.70,

75

If the

shortcomings of peptides, such as poor membrane permeability or poor metabolic
stability could be overcome, peptides would be ideal drug candidates.70,

75

There are

many ongoing studies to improve peptide-based ligands as potential drugs (Figure
1.9).75-76

Figure 1.9. A generic peptide structure along with some possible modifications is
depicted.
One of the methods for improving peptide function is conjugating them to a moiety that
has desired activity, such as increasing cell permeability or potency.77-79 In general,
peptides tend to have poor cellular delivery, which can be improved by attaching a
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hydrophobic chain, lipids, or sugar moieties. Similarly, conjugating a peptide to a potent
drug molecule can lead to synergistic effects.80
A weakness of peptides as drugs is their short half-life due to degradation by
peptidases.81-83 However, several methods utilize D-amino acids, non-natural amino
acids, peptoids, or cyclization to decrease recognition and breakdown by peptidases,
thus improving drug stability.81, 84-85 Synthetic peptides have other advantages as drug
leads because they can be improved in relatively easy fashion, through methods such as
peptide scanning of alanine, proline, or D-amino acids.83, 86-87 Through amino acid scans,
important residues for the configuration and activity of a peptide can also be
determined.83 Peptoids employ N-substituted glycine to alter the peptide backbone and
make it resistant to peptidases.88 Furthermore, various functional groups can be
attached to the amino group, allowing development of large combinatorial libraries.89
Combinatorial libraries have been widely used, not only to screen for new drugs
against known targets, but also for known drugs against new targets.90 In addition,
structure-activity relationship (SAR) studies that employ molecular dynamics simulations
to predict or optimize new drugs have been increasing in the medicinal chemistry field,
particularly due to advances in computational chemistry.76-77,

91

For such applications,

peptides are typically easier to synthesize than complex natural products. Nowadays,
development of native chemical ligation or click chemistry has also allowed for larger
peptides to be generated and tested for activity.92-93
1.3.2. Antimicrobial peptides
In nature, antimicrobial peptides (AMPs) are produced in plants, fungi, and animals, so
that the organisms can protect themselves from microorganisms. The first AMP,
defensin, was discovered through extraction from soil by Dubos in the 1930s.94 Some
examples of antimicrobial peptides are listed in Table 1.2. Most AMPs target the cell
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membrane, strongly relying on their highly charged structures.95-96 Some of the
commonly used AMPs target the ribosome as well.84
Table 1.2. Antimicrobial peptides and their targets
name

description

mode of action

defensin94

Cys-rich cationic antimicrobial
peptide (AMP) forming β sheets

forms pores in membranes,
inducing ion loss

vancomycin97

tricyclic branched glycopeptide

inhibition of cell wall synthesis

capreomycin98

cationic cyclic peptide

inhibition of translocation by
interacting with h44 and H69 of
70S ribosomes

edeine6

pentapeptide with non-natural
amino acids and a polyamine

translation-initiation inhibition by
targeting the 30S subunit

thiostrepton99-100

macrocyclic thiopeptide with
multiple post-translational
modifications

translation inhibition by blocking
IF2 and EF-G

daptomycin101

13-mer cyclic peptide with a
decanoyl group attached

disrupts cell membranes by
forming aggregation that makes
pores, leading to ion loss

In Figure 1.10, the structures of several AMPs are shown. Vancomycin (Figure 1.10a)
is a glycosylated cyclic peptide that disrupts cell wall synthesis. Unlike the well-known
penicillin that forms a peptidoglycan intermediate with a β-lactam, vancomycin blocks
transpeptidation and transglycosylation by forming five hydrogen bonds with the
peptidoglycan, a property that is enhanced by the concave structure of the drug.102
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Figure 1.10. The chemical structures of several antimicrobial peptides
Daptomycin is a membrane-active lipopeptide that was originally extracted from S.
roseosporus and is now produced synthetically.96 Daptomycin has a cyclic peptide
structure with D-amino acids and a hydrophobic decaonyl chain.103 The decanoyl chain
attaches the peptide to the membrane. As can be seen in Figure 1.10b, the peptide
structure contains multiple carboxylic acid groups, making it negatively charged. 103 The
anionic peptide attracts Ca2+ ions, and after the decanoyl chain attaches itself to the
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membrane, a micelle-like structure of daptomycin forms a pore and disrupts the
membrane.96
Edeine (Figure 1.10c) targets the 30S subunit and inhibits translation initiation by
blocking fMet-tRNA binding at the P site (peptidyl site).6,

104

Edeine possesses non-

natural amino acids such as β-serine, 2,3-diaminopropanoic acid (DAPA), 2,6-diamino-7hydroxyazelaic acid (DAHAA), β-tyrosine, and spermidine, which make this molecule
highly positive. The cationic nature of the peptide facilitates its interactions with
negatively charged rRNA.
The ribosome is a common target for AMPs. Capreomycin (Figure 1.11) and viomycin
inhibit translocation by interacting with h44 and H69 of the 70S ribosome.98,

105

Capreomycin is a cyclic peptide containing a decanoyl chain and amino groups that
provide cationic properties. The constrained ring structure allows capreomycin to
position itself in the binding pocket that includes A1493 of h44 and A1913 and C1914 of
H69.106 Another peptide drug oncocin targets the 70S ribosome by blocking access to
the A and P sites, PTC, and the peptide exit tunnel of the 50S subunit.107 The AMPs are
typically rich in cationic residues and interact with the ribosome through H-bonding,
charge-charge, or π-interactions, which can be weakened by modification.105, 107

Figure 1.11. Antibacterial peptide capreomycin IB, a drug that targets the ribosome,
interacts with A1492, A1493, and G1491 of h44, and A1913 and C1914 of H69 and
acts by disrupting the interface between h44 and H69 (PDB ID 3KNO).106
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1.4. Background on techniques used in this study
1.4.1. Phage display
Phage display was developed by George P. Smith in the early 90s.108-109 Phage
display is a biological tool that uses phage particles to express peptides on their
surfaces, which can be used to select peptides that have binding affinity to a target of
interest.109 In this study, the Ph.D.-7 library from New England Biolabs was used. This is
a linear heptapeptide library of 207 size complexity (diversity). By integrating DNA
sequences encoding the peptide that will be expressed on the pIII coat protein into the
M13KE vector, a randomized phage library is obtained. The pIII coat protein is a minor
protein among those proteins that comprise the phage particle, which allows it to attach
and infect the host. The pIII coat protein is composed of five copies of proteins, to which
the randomized peptides are attached through their N-termini (Figure 1.12). Therefore,
five copies of the peptides are expressed on the phage surface. The diversity in peptide
sequences is 20n (where n is the number of amino acids in the peptide), and therefore a
pool of peptide ligands can be expressed and selected for affinity to a given target.109-110
The foreign peptide or protein can also be engineered to be attached to other coat
proteins or antibodies or manipulating the number of peptides displayed.111-114

Figure 1.12. A generalized structure of M13 phage used for phage display
The DNA of the phage encode a lac operon to allow for blue/white screening.
Therefore, after each round of selection, the phage can be titered and quantified. Phage
titering is an important technique for molecular biology, and in this case, for the phage
display method. Following a selection experiment, it is of interest to determine the phage
population. In order to quantify this process, the number of phage plaques were counted
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after each step of biopanning. Ideally the number of plaques should be about 50 to 500
on each agar plate. Because the phage are viruses, they can use a host such as E. coli
to reproduce. For the commercial Ph.D.-7 libraries, randomized peptide sequences are
inserted into the vector M13KE to be expressed on the N-terminus of the pIII coat
protein.115-117 The peptide sequences are inserted in between restriction enzyme sites
EagI and KpnI, with Gly-Gly-Gly-Ser in between the peptide sequence and the pIII
surface. A yield can be obtained for the phage selection by comparing the number of
input and output phage. Following this step, the phage are amplified using E. coli as a
host. This step provides enough phage to carry out the biopanning step again. In the
case of the Ph.D.-7 library, the initial selection step starts with 207 clones, which contain
1.3 million different sequences with 70 copies each. Thus, carrying out 3 to 4 rounds of
selection and getting hundreds of sequences are necessary to identify consensus motifs.

Figure 1.13. A general scheme of phage display (biopanning procedure) is shown. To
a random phage library, biotinylated target is added. Following incubation,
streptavidinlyated magnetic beads are added, and after several washing steps, the
bound phage is isolated. Specific/nonspecific elution allows disruption of the complex
of phage/target on streptavidinlyated magnetic beads and bound phage are obtained.
The bound phage are amplified using E. coli as the host. After several repeated rounds
of biopanning, the DNA encoding the peptides binding to the target can be identified.
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The general protocol (referred to as biopanning) for the phage display experiment is
summarized in Figure 1.13. The library is incubated with a target that is attached to a
surface such as a magnetic bead using streptavidin-biotin chemistry. The phage having
affinity to the target can be isolated after the washing steps. In nonspecific elution,
noncovalent interactions of the target and phage are disrupted by adding an acidic buffer
and the bound phage are released from the target. Specific elution involves incubation
with a non-biotinylated target that competes for binding to the selected phage with the
immobilized target. Addition of either the target or a variant of the target for counter
selection allows for selective elution of phage with affinity for a given molecule, rather
than eluting all bound phage that may include some nonspecific binders.
In previous studies in our lab, phage display has been performed under physiological
buffer systems against h31, h44, or H69.118-120 In this thesis work, phage display against
H69 was done under several different buffer conditions, and mainly focused on phage
display at low pH (pH 5.5). A previous study employed phage display at low pH to select
peptides targeting amylases.121 The low pH was shown to increase binding of phage to
the target; however, overall phage survival was lower and more polar sequences were
selected.121 In this study, selection was carried out with nonspecific elution to ensure
higher yields of bound phage. To our knowledge, there have not been phage display
studies done at low pH against RNA.
One challenge in this study, which will be discussed in a later chapter, is that our RNA
target is an essential component of the bacterial ribosome. Because we use E. coli as
the host for amplification, any peptides that display antibiotic activity through rRNA (H69)
targeting will be lethal, and therefore will not be amplified. Therefore, the possibility of
selecting a peptide that is fatal for the host is low. Also, some phage are known to be
fast growers over other phage, which can decrease the chance of slow-growing phage to
be potent. However, considering that the small peptides selected through phage display
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are likely to have only moderate binding affinities, the selected peptides will be
considered only as starting peptides (i.e., “parents”) that can further be modified through
amino acid scanning or structure-activity relationship (SAR) studies.
1.4.2. Solid-phase peptide synthesis
Solid-phase peptide synthesis was first developed by Bruce Merrifield in 1963,
proceeding through anchoring the C-terminus of an amino acid onto a solid support.71
The solid supports are polymer-based resins, and the functional groups vary so that the
C-terminus of the cleaved peptide can be a carboxylic acid or an amide.122 Depending
on the size or use of the desired peptide, one can choose resins with different loading
levels or swelling properties.
Usually amino acids with a fluorenylmethyloxycarbonyl (Fmoc) on the N-terminus are
employed (Figure 1.14), wherein Fmoc is a base-labile protecting group.123-124 The side
chains are typically protected with acid-labile protecting groups. Having orthogonal
protecting groups is essential for the sequential addition of selected amino acids.125

Figure 1.14. Structures of reagents commonly used in solid-phase peptide synthesis
are shown.
Addition of Fmoc-protected amino acids is done with carboxylate-activating coupling
reagents, such as N,N’-dicyclohexylcarbodiimide (DCC).71 Hydroxy groups are poor
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leaving groups, so addition of a carbodiimide activates them to increase the
electrophilicity of the carbonyl group. To the reaction, the coupling agent is added at a
concentration of 2 equivalents (2 eq.) relative to the amount of resin (i.e., if there is 1 g of
0.68 mmol/g, 1 eq. is 0.68 mmol), along with 2 eq. of Fmoc-protected amino acids, to
facilitate the reaction. However, the byproduct of the reaction is urea-based, and in the
case of DCC coupling, racemization can occur.126 To reduce this problem, phosphonium
salts

such

as

hexafluorophosphate,

Castro’s
BOP)

or

reagent

(benzotriazol-1-yloxytrisphosphonium

O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium

hexafluorophosphate (HBTU) were developed as alternative coupling agents.127
Additives such as 1-hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole
(HOAt) may also be added to increase the rate and yield of the reaction.126 In addition, 4
eq. of diisopropylethylamine (DIPEA) are added to deprotonate the carboxylic acid as
well as the amino groups of the Fmoc-protected amino acids. Coupling with these
reagents allows a one-pot synthesis of the peptides to be done.
Scheme 1.1. Structures of the resins used in this study with a general scheme of solidphase peptide synthesis
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As shown in Scheme 1.1, Fmoc-protected amino acids and coupling reagents are
added to the resin, followed by deprotection of the Fmoc group using 20%
piperidine/DMF. This step is generally performed by adding the basic solution once for 5
min, the solution is then removed, followed by addition of the basic solution for an
additional 7 min.
When the peptide coupling steps are completed, the final Fmoc protective group is
removed, the peptide is cleaved from the solid support, and removal of the acid-labile
protecting groups are removed by using a "cleavage cocktail".128 The cleavage cocktail
typically contains trifluoroacetic acid (TFA) with various scavengers, such as
triisopropylsilane (TIPS), thioanisole, phenol, and water. When the protecting groups are
cleaved by TFA, radicals can be formed, which can react with the peptide products.
Therefore, scavengers are added to increase the purity of the products by capturing the
protecting groups. The concentration of each component varies depending on the
protecting group or resin in use.
Following incubation with the cleavage cocktail, the slurry is filtered into cold diethyl
ether to precipitate the peptide, and after several washes, a crude peptide is obtained.
For short peptides, or those with high solubility in ether, precipitation may be inefficient,
wherein extraction with organic solvents may be needed. For further purification, high
performance liquid chromatography (HPLC) is typically used. In cases in which the
peptide is insoluble in water due to high hydrophobicity, HPLC cannot be used for
purification. In such cases, extraction in organic solvents followed by column
chromatography or prep-TLC (thin layer chromatography) can be used.129
Solid-phase peptide synthesis has been widely used because of its advantages
compared to conventional solution-phase organic synthesis.124-125 In general, the
procedures are relatively simple and the products can be obtained with high yields and
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purity because of the washing and filtering steps, which can also be automated. Unlike
natural products that require multi-step syntheses in controlled systems, peptides are
easier to synthesize and modify. Therefore, with starting parent sequences or motifs, the
development of a potent therapeutic by rational design has been emerging. 130-131
Development of peptoids, cyclic peptides, and multimeric peptides has expanded the
range of peptide-related drugs.89, 130, 132,133 Pharmaceutical research can now leverage
these tools in discovery of peptide-related drugs.
1.4.3. Fluorescent intercalator displacement (FID) assay
Fluorophores (or dyes) absorb specific wavelengths of light (excitation), followed by
emission as they relax.134 Due to the fact that one can selectively monitor a molecule
with fluorescence spectroscopy, many binding studies rely on fluorescence by attaching
a dye to the molecule of interest (i.e., the target).67, 135-136 However, because the dye tag
can alter binding affinities of the target, label-free methods are preferred if possible. Most
fluorophores used in fluorescence studies have planar structures with multiple aromatic
rings conjugated with high resonance, which not only delocalizes the electrons, but allow
for favorable interactions with DNA or RNA. A fluorescent intercalator displacement
(FID) method is a label-free experiment involving a dye that fluoresces only when it is
intercalated or surface bound to the target.137-141 The fluorescence then generally
decreases if a ligand binds and removes the dye through direct or indirect displacement,
such as changing the conformation of the target.140-141 The FID assay has several
advantages as a screening assay. First, utilization of a sensitive dye requires only a low
amount of material (for both the dye and target). Second, this assay is simple, both in
terms of sample preparation and data collection, compared to methods such as surface
plasmon resonance (SPR) or electrospray ionization mass spectrometry (ESI-MS) (see
Sections 1.4.4 and 1.4.5). Third, physiological buffers are typically suitable for use in
these experiments, which is not possible with ESI-MS or nuclear magnetic resonance
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(NMR). However, there are some weaknesses with the method. One weakness is that
only a change in signal is detected, indicating a binding event, but not the binding site.
Another shortcoming is that because the dye is displaced by a ligand under equilibrium
conditions, there is competition between the ligand and dye for the target, which makes
the FID assay a qualitative rather than a quantitative method. In addition, a lack of
fluorescence change does not necessarily mean that a binding event did not occur.
Despite the shortcomings noted, this method is still relatively fast and can be used in a
96- or 386-well plate format, making it a good tool for high throughput screening
(HTS).138

Figure 1.15. The general scheme for the FID assay is shown. To the target (nonfluorescent), a dye is added that fluoresces when bound. Addition of a molecule (nonfluorescent ligand) that can remove the dye by direct displacement or by a change in
target conformation leads to decreased fluorescence.
1.4.4. Electrospray ionization mass spectrometry (ESI-MS)
Electrospray ionization mass spectrometry (ESI-MS) is a soft ionization technique that
can be used to determine the mass of a molecule or a target-ligand complex.142 The
method has many strengths. ESI-MS is very sensitive, therefore only requires a small
amount of sample (pmol to low nmol range), which does not need to be labeled or
tagged. In addition, the apparent dissociation constant, or Kd, and stoichiometry of the
complex can be obtained. The components of a mass spectrometer typically include an
ionizer, analyzer, and detector (Figure 1.16). The electrospray process nebulizes the
liquid to form highly charged droplets, then a heated nitrogen gas helps to evaporate the
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solvent and reduce the droplet size.143-144 The charges move to the surface to minimize
Coulombic repulsion and form ions, and as the solvent evaporates the droplet sizes get
smaller. When the Coulombic repulsion exceeds the surface tension (Rayleigh limit), the
droplets explode to make smaller droplets.142 This step leads to fragmentation of the
droplet. Compared to laser-assisted methods such as MALDI-TOF, ESI-MS is a soft
ionization method. The droplets travel through the analyzer, which filters the ions
according to their mass-to-charge ratio (m/z). Those that reach the detector are recorded.
The soft ionization of ESI-MS allows noncovalent interactions of complexes to be
monitored.142,

145

Therefore, this method is a powerful tool for examining binding of

various ligands to biomolecules such as RNA.146-147 ESI-MS also provides the
stoichiometry of the complexes, which is an advantage when trying to understand ligand
binding modes.

Figure 1.16. A general depiction of ESI-MS is given. In RNA-peptide binding studies,
the negative ion mode is used. The negative charges on the RNA are neutralized by
NH4+, and AcO- ions are located on the surface of the droplets, which does not change
the overall charge of the molecule. As the negatively charged droplets travel through
the source region or mass analyzer, they break into smaller droplets due to Coulombic
repulsion, and reach the detector as single ions.
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As with the other methods mentioned, there are limitations to the ESI-MS method. The
ideal salt concentration of the buffer used in ESI-MS experiments is usually 10-20 mM,
which is much lower than physiological conditions.148 Furthermore, Na+ or K+ typically
need to be eliminated, because adducts with these salts can give poor fragmentation
and high noise levels. Studies have shown that an increase in the salt concentration also
alters the charge state distribution, and can disrupt hydrophobic interactions between
molecules.149-150 Volatile solvents such as acetonitrile or isopropanol are typically
employed in ESI-MS. Although these solvents are not physiological buffers, they can
help the droplet formation by decreasing the surface tension.145 The ionization
efficiencies of the free target and complex can be different.146 Therefore, it is necessary
to use complementary methods to verify the binding constants obtained from ESI-MS.
1.4.5. Surface plasmon resonance (SPR)
1.4.5.1. The principle of SPR on Biacore
As mentioned in previous sections, binding affinities or dissociation constants can be
measured using a variety of methods, each with advantages and limitations. Surface
plasmon resonance (SPR) (e.g., Biacore) is another powerful method to study
biomolecular interactions.151 A surface plasmon is an electromagnetic wave that occurs
when a beam of incident light is shone onto a prism with a thin gold surface. The light
generates an evanescent wave with refraction occurring along with reflection (Figure
1.17a). At the angle where there is total reflection and no refraction, the angle is called
the total internal reflection (TIR). At an angle that is larger than TIR, surface plasmon
resonance (SPR) takes place, and the energy of the photon converted into a plasmon
creates a dark band in the reflected light (Figure 1.17b). The dark band shifts when
there is a change in the refractive index (i.e., change on the surface mass). The TIR
angle is related to the mass of the surface, and a mass change results in a shift of the
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TIR angle. Therefore, by monitoring the change of mass on a surface with an
immobilized target, binding of a ligand can be quantified (Figure 1.17c and 1.17d).152-153

Figure 1.17. A description of surface plasmon resonance is given. a) The light shone
generates an evanescent wave, with refraction occurring along with reflection. The
angle where there is total reflection and no refraction is called the total internal
reflection (TIR). b) At an angle that is larger than TIR, surface plasmon resonance
(SPR) takes place, and the energy of the photon converted into a plasmon creates a
dark band in the reflected light. c) The TIR angle is related to the mass of the surface,
and a mass change results in a shift of the TIR angle. d) By monitoring the change of
the TIR angle, and thus the mass, on a surface with an immobilized target, binding of a
ligand can be quantified.
The SPR method also has several strengths and weaknesses. SPR requires only
small amounts of material (pmol to nmol) compared to NMR spectroscopy. By flowing
through ligands (called “analytes” in SPR)152 that have affinity to the immobilized target
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(often called “ligand” in SPR), real-time binding can be monitored. This method provides
information of kinetics of the interaction along with the apparent dissociation constant. In
this case, a wide range of buffers can be used, which allows studies to be carried out
under differing conditions including physiological salt concentrations and pH values.
Thus, the ability to obtain kinetic information under high salt conditions makes this
method advantageous compared to ESI-MS or NMR spectroscopy.
Despite the advantages of SPR, the Biacore system requires use of an expensive
sensor chip. In order to immobilize a molecule onto the sensor chip, a tag such as biotin
needs to be attached to the target. Also, the signal detected is correlated with the
change in mass of the surface; therefore, when a lighter molecule is immobilized as a
target, the change of signal when a larger ligand binds is detected more clearly.154 For
studies of RNA-peptide interactions, the RNA is usually immobilized to the surface due
to its high cost. To increase the response to smaller ligands, RNA is typically
immobilized in high density.155 As a result, mass transport can also be a problem, which
is caused when the binding rate of the ligand to the target is faster than diffusion. 156
Smaller amounts of the target need to be immobilized in order to minimize mass
transport effects. In RNA-peptide binding studies, this can cause a conflict with the need
for higher loading levels of RNA. Therefore, optimization is required to find the maximal
amount of target to immobilize in order to reduce mass transport problems.
1.4.5.2. Bio-Layer Interferometry (BLItz)
SPR is an ideal method for monitoring biomolecule interactions; however, the Biacore
system is not cost or time efficient compared to methods such as FID. Recently,
companies have been developing more cost-effective instruments that operate with
similar methods.157-158 For example, bio-layer interferometry (BLItz) is one of those
techniques.157, 159-161 Though the actual mechanism of the technology is proprietary, the
method is based on SPR using white incident light. The light is shone onto the biosensor
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with a target immobilized, and when there is a change on the surface, the signal
obtained from the biosensor changes. However, a detailed mechanism of the instrument
is not provided.

Figure 1.18. A schematic diagram of BLItz is shown. a) The sensor components are
given. To an optical sensor with streptavidin, a biotinylated target can be immobilized.
b) For association, the sensor with the target immobilized is dipped into a buffer
containing the ligand, and the association is observed. c) The sensor from b) is dipped
into buffer, and the dissociation is measured.162

There are two differences between this method and Biacore SPR. One is that the
sensor is on a tip that can be easily removed and immobilized with target. The other
difference is the association/dissociation method.157, 162 In Biacore, there is a flow of the
buffer containing ligand to allow for association and dissociation.162 In BLItz, the tip
sensor is place into a solution containing the ligand for the association step (with
agitation of the sample), and then the tip sensor is placed into another buffer for the
dissociation step (Figure 1.18).161 In SPR, the concentration of the ligand solution or
buffer stays constant but is flowing over the target. In BLItz the concentration of the
ligand solution or buffer may decrease or increase during the association or dissociation
step, which may affect the true binding. Therefore, to minimize concentration effects,
fresh samples are required, and the sample is agitated takes place while monitoring
association and dissociation.
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1.4.6. Nuclear magnetic resonance (NMR) spectroscopy
NMR spectroscopy is a useful technique for observing RNA structure in solution. Each
nucleus of a molecule has an electric charge and spin, which gives a unique chemical
shift when an external magnetic field applied. Depending on the chemical environment of
the atom, which can vary with neighboring functional groups or interactions, the chemical
shifts or coupling patterns are affected. In this study, 2D proton homonuclear correlation
spectroscopy (ge-2D COSY) was used to monitor the resonance from the crosspeaks
between the H5 and H6 of pyrimidines.163 This method detects proton coupling; therfore,
a change in the chemical environment upon ligand binding can be monitored. Compared
to other 2D NMR experiments, COSY experiments require less sample (3 OD, 15 nmol).
Therefore, for binding experiments with expensive targets such as the RNA, COSY was
selected as the best NMR method.
There are strengths and limitations to NMR spectroscopy. When there is a change in
the chemical shift, this typically indicates a change in the local chemical environment
such as an altered conformational state of the molecule or interaction with a ligand. In
this thesis work, NMR spectroscopy was used for RNA-peptide binding studies. This
method can give information about the binding site (i.e., which nucleotides interact with
the ligand), which is not obtained directly from SPR or fluorescence studies. However,
NMR requires large amounts of highly pure sample. Synthetic RNA, which is typically
necessary for modified samples, is expensive; therefore, this method is not as costefficient as ESI-MS or fluorescence studies. Because of the various limitations, it is best
to have more than one method to obtain the apparent dissociation constant (Kd) for a
target-ligand complex. In Table 1.3, the strengths and limitations of the approaches used
for binding studies in this thesis work are summarized.
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Table 1.3. A comparison of various biophysical methods for determining RNA-ligand
interactions.
Method

Advantages


FID
assay

ESI-MS





pmoles of sample required
(both dye and target)
simple to perform
label-free
physiological buffer can be
used




pmoles of sample required
apparent Kd values obtained






SPR

BLItz

stoichiometry obtained
label-free



pmoles of sample required
physiological buffer can be
used
apparent K values obtained



kinetic information obtained



more cost and time effective
compared to SPR
pmoles of sample required
physiological buffers can be
used
apparent Kd values can be





d

Disadvantages


cannot




directly
cannot determine stoichiometry
changes in fluorescence are
difficult to predict or interpret

obtain

apparent

Kd




cannot use physiological buffers
extensive sample purification
required




need to label the target
typically the ligand needs to be
larger than the immobilized
target
expensive instrumentation and
consumables







need to label the target
typically the ligand needs to be
larger than the immobilized
target
expensive consumables

obtained

NMR




label-free
binding site of a ligand can be
determined





large amount of sample required
limitations on buffers
challenging to obtain apparent
K values



challenging
stoichiometry

d

to

determine

1.5. Overall project objective
Due to the rise of antibiotic resistance, there is a need for discovery of new targets
and development of novel drugs. In our laboratory, we are interested in helix 69 (H69),
an rRNA motif located in the B2a intersubunit bridge of the bacterial ribosome.164 Helix
69 interacts with helix 44 (h44), A-tRNA, P-tRNA, RF, and RRF, and forms an
intersubunit bridge B2a with h44, which makes it an interesting target.30-32, 48, 165 Helix 69

30
also has post-transcriptionally modified nucleosides, pseudouridine (Ψ) and methylated
pseudouridine (m3Ψ).48 Pseudouridine increases the stability of the helix by increasing
base stacking, and is conserved across phylogeny.47-48,

166

Helix 69 shows different

conformations in 50S subunits and 70S ribosomes, which can be altered by changing
buffer conditions or temperature of the system.66-67 The goal of this project was to select
a peptide ligand for binding to modified H69 in the stacked-in conformation. If we are
able to find a peptide ligand that can bind to H69, this ligand may be able to disrupt H69
interacting with other factors or rRNAs, which will inhibit translation. Phage display was
used to screen a peptide library under low pH conditions (pH 5.5) with tRNAPhe as a
competitor to eliminate nonspecific binding peptides.
The binding studies were performed on model systems. The various methods used
were in vitro experiments, which give information on the binding interactions in a
controlled environment outside of the cell. Although the binding may differ in vivo, the in
vitro experiments allow observations of the binding interactions at the molecular level. In
this work, in vitro studies are useful because we can observe binding events at both pH
5.5 and pH 7.0 conditions for both ΨΨΨ and UUU H69, which is not possible for in vivo
studies. By utilization of multiple methods, we were able to obtain information on the
relative affinities and modes of binding, stoichiometries, and interaction sites for the
peptide ligands. We hope these studies provide information for future studies on peptidebased antibacterial drugs.
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CHAPTER 2 – METHODS AND EXPERIMENTAL DESIGN
2.1. Preparation of the RNA
Modified H69 ΨΨΨ (5′-GGCCGΨAACΨAΨAACGGUC-3′) was purchased from Thermo
Fisher Scientific (Waltham, MA) on a 1 μmol scale and unmodified H69 UUU was
obtained by T7 RNA transcription as described below. Adenosine triphosphate (ATP),
cytidine triphosphate (CTP), guanosine triphosphate (GTP), uridine triphosphate (UTP),
acrylamide, bisacrylamide, urea, sodium acetate (NaOAc), triethylammonium acetate
(TEAA), acetic acid (CH3COOH or AcOH), hydrochloric acid (HCl), ammonium persulfate
(APS), acetonitrile (MeCN), sodium hydroxide, zinc chloride (ZnCl2), ethanol, Microcon 3
(centrifugal filter unit YM-3 membrane), and alkaline phosphatase were purchased from
Sigma-Aldrich (St. Louis, MO). Tris, boric acid, ethylenediaminetetraacetic acid (EDTA),
dithiothreitol (DTT), spermidine, Triton X-100, ammonium acetate (NH4OAc), and
tetramethylethyldenediamine (TEMED) were purchased from Fisher Scientific (Hampton,
NH). XTerra C18 column (10 x 50 mm, 2.5 μm) and Sep-pak SPE columns were
purchased from Waters (Milford, MA) for a Waters 600 LC with a 717 autosampler
(Waters, Milford, MA, USA) and UV-detector.
The H69 UUU was synthesized using T7 in vitro transcription.166-167 To HPLC-purified
DNA template (5′-GACCGTTATAGTTACGGCCTATAGTGAGTCGTATTA-3′) (10 μg, 0.9
nmol) and T7 promoter (5′-TAATACGACTCCTATAGG-3′) (4.9 μg, 0.9 nmol) in 1 mL of
1× transcription buffer (40 mM Tris-HCl, 2 mM spermidine, 0.01% Triton X-100), was
added 7 mM NTPs, 10 mM DTT, and 100 U of T7 RNA polymerase (Epicenter, Madison,
WI), followed by incubation at 37 °C for 4 h. The transcribed RNAs were purified on 20%
denaturing polyacrylamide gels with 19:1 acrylamide/bisacrylamide, 1× TBE buffer (90
mM Tris, 90 mM boric acid, 1 mM EDTA, pH 8.2) and 7 M urea. The RNA band was
visualized using UV shadowing, followed by excision and extraction through the crushand-soak method. After eluting the RNA, ethanol precipitation using 1/10th volume of 3 M
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NaOAc was performed to desalt. Desalted RNA was then characterized by using
MALDI-TOF MS as described below. Negative mode on Ultraflex Extreme TOF/TOF
from Bruker (Billerica, MA) was used for detection. Three-Hydroxypicolinic acid (HPA)
was used as the matrix.
Modified H69 ΨΨΨ was purified by HPLC (XTerra C18) in 25 mM triethylammonium
acetate (TEAA), pH 6.5, by increasing the MeCN concentration from 6 to 12% over 30
min at a flow rate of 4 mL/min. The collected sample was dried in vacuo, followed by
ethanol precipitation. The RNA was characterized by MALDI-TOF MS and 20% PAGE.
For MALDI-TOF MS, 10 pmol of H69 ΨΨΨ in 1 μL of ddH2O, 1 μL of supersaturated
matrix and 0.05 μL of 10 mM NH4OAc were mixed and allowed to dry on a 384-well
metal plate before measurement. Negative ion mode on Ultraflex Extreme TOF/TOF
from Bruker (Billerica, MA) was used for detection, and 3-hydroxypicolinic acid (HPA,
Figure 2.1a) was used as the matrix. After HPLC, the RNA purity was also checked by
running denaturing 20% polyacrylamide gel electrophoresis (PAGE).

Figure 2.1. Structures of matrices used for MALDI-TOF studies are shown.

Digestion with P1 nuclease followed by HPLC analysis was used to confirm the
presence of pseudouridine in the H69 ΨΨΨ sample. To 0.1 OD of H69 ΨΨΨ in 86.25 μL
of ddH2O was added 10 U of P1 nuclease, 2.5 μL of 10 mM ZnCl2, and 1.25 μL of 3 M
NaOAc. The mixture was incubated at 37 °C for 18 h, followed by centrifugation at 5000
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rpm for 30 min through a Microcon 3 filter. Then, to 60 μL of the flow-through was added
5 μL of alkaline phosphatase and 3.6 μL of 1 M Tris-HCl (pH 8), and the mixture was
incubated at 37 °C for 4 h, followed by centrifugation at 5000 rpm for 30 min through a
Microcon 3. The flow-through was diluted to 100 μL, followed by separation by HPLC. A
Discovery C18 column (Supelco C18 4.6 × 250 mm, 5 µm, Sigma-Aldrich, St Louis, MO,
USA) on a Waters 600 LC with a 717 autosampler (Waters, Milford, MA, USA) and UVdetector was used for separation of the mixture, with 40 mM NH4OAc and 40% MeCN
used as the buffer. The column was equilibrated with 40 mM NH4OAc, and the eluents
were separated with increasing concentration of MeCN from 0 to 12% over 30 min.
For studies such as ESI-MS and NMR studies that are sensitive to impurities and
buffer conditions, extensive desalting of the RNA is required. In addition to ethanol
precipitation, Sep-pak SPE columns were used for desalting. Each desalting process
was done on 50 nmol or less of RNA. The column was first activated by using 10 mL of
MeCN, followed by washing the column with 10 mL of ddH2O. After the column was
washed, the RNA was loaded to the column, followed by washing the RNA with 20 mL of
ddH2O. After desalting, the RNA was eluted with 30% MeCN in ddH2O. The eluted RNA
was quantified with UV spectroscopy, and lyophilized before use. The extinction
coefficients for ΨΨΨ and UUU H69 were 187,000 Lmol-1cm-1 and 189,400 Lmol-1cm-1,
respectively.45
2.2. Phage display performed against H69
2.2.1. Biopanning
In this study, buffers with differing pHs were used for RNA binding. For higher pH
conditions, 20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1
mg/mL BSA with 0.1% (v/v) Tween-20 (buffer A) was used, and for the lower pH buffer,
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v) Tween20 (buffer B) was used. To 200 μL of buffer A or B in 1 mL microcentrifuge tube was
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added the phage library pre-incubated with M-280 streptavidin-magnetic beads (2  1011
pfu) and 30 pmol of target (biotinylated UUU, 10 µM, Figure 2.2).

Figure 2.2. Structure of biotinylated H69 UUU is shown.

The mixture was then incubated at room temperature (RT) for 30 min. After incubation
with RNA, the beads were washed with 200 μL of the buffer five times. After mixing, the
beads were held against the sample with a magnet, spun down using a microcentrifuge,
then the supernatant was carefully decanted into another microcentrifuge tube. Next,
200 μL of buffer was added, and mixing, centrifugation, and removal of the supernatant
was repeated five times. For elution of the phage, the beads were placed in 100 μL of
buffer C (0.2 M glycine-HCl, pH 2.2, 1 mg/mL BSA) for 9 min, followed by neutralization
with 15 μL of buffer D (1 M Tris-HCl, pH 9.1). Then, 10 μL of the eluate was removed
and placed in a separate 500 µL microcentrifuge tube for titering, and 100 μL of the
eluate was kept for the next step.
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Table 2.1. Dilutions prepared for phage libraries

To 5–10 mL of LB, a single colony from E. coli strain ER2738 (New England Biolabs,
Ipswich, MA) from a plate was inoculated and incubated at 37 °C with shaking to mid-log
phase (OD600~0.5, 4–8 h). Then, to a pre-warmed LB/IPTG plate per expected dilution
was spread at 37 °C until ready for use. The serial dilutions were prepared in the
following manner (Table 2.1).

Figure 2.3. Schematic figure of the steps performed after biopanning is shown.
When the culture reached mid-log phase, 200 μL of the culture was dispensed into
microfuge tubes, which held phage dilutions. Then, to carry out infection, 10 μL of each
phage dilution was added to a tube, vortexed quickly, and incubated at room
temperature for 1–5 min. The infected cells were vortexed briefly, and the culture was
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immediately poured onto a pre-warmed LB/IPTG plate. The plates were allowed to cool
and dry for 5 min, inverted, and incubated overnight at 37 °C. Plaques on plates were
counted that have approximately 100. To each number, the dilution factor was multiplied
for that plate to get the phage titer in plaque forming units (pfu) per 10 μL, and the %
yield of the output/input phage was calculated using Equation 2.1.
Equation 2.1.
% yield = 100  (# of output phage  dilution factor) / # of input phage

Figure 2.4. A schematic representation of specific elution is given. A nonbiotinylated
target is added to the complex of phage/target on streptavidinylated magnetic bead to
wash off the phage that bind selectively to the biotinylated target.
Phage display was performed under various conditions, including pH 5.5 to favor the
closed conformation, and at higher Mg2+ concentrations to favor the open conformation.
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Elution was done with differing competing RNAs, such as the H69 stem region, human
H69, and tRNAPhe to improve peptide selectivity. The elution was performed nonspecifically and specifically. Non-specific elution was performed with an acidic glycine
buffer, whereas specific elution was performed by eluting the phage with free target
(Figure 2.4).
The conditions for washing and elution are displayed in Table 2.2. The selections were
separately performed from round 3, and biopanning using M-280 streptavidin-coated
magnetic beads and H69 with various competitors is shown. The washing buffer is the
same as the binding buffer (buffer A minus Tween-20) with addition of different
concentrations of Triton X-100. For the first two rounds, only tRNA was used as a
competitor and only non-specific elution was performed. For specific elution, after two
rounds, 3 eq. of free (nonbiotinylated) H69 UUU (90 pmol) were added to the solution
with biotinylated H69 ΨΨΨ and phage that were washed before addition of the H69 UUU.

Table 2.2. Biopanning conditions for rounds 1-4 (pH 7.0)
round

washing

H69
(pmol)

competitor RNA
(pmol)

binding
time (h)

elution

1

3 times, 0.1%
Triton-X

30

90 (tRNA)

2

non-specific

2

3 times, 0.3%
Triton-X

30

90 (tRNA)

2

non-specific

3

10 times,
0.5% Triton-X

30

90 (human H69, H69
UUU, H69 stem, tRNA)

1

non-specific
and specific

4

10 times,
0.5% Triton-X

30

90 (human H69, H69
UUU, H69 stem, tRNA)

0.5

non-specific
and specific

Biopanning using M-280 streptavidin-coated magnetic beads and H69 at pH 5.5 is
shown in Table 2.3. The washing buffer is the same as the binding buffer (buffer B
minus Tween-20) with addition of different concentrations of Triton X-100.
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Table 2.3. Biopanning conditions for rounds 1-4 (pH 5.5)
round

washing

H69
(pmol)

competitor RNA
(pmol)

binding
time (h)

elution

1

3 times, 0.1%
Triton-X

30

90 (tRNA)

2

non-specific

2

3 times, 0.3%
Triton-X

30

90 (tRNA)

2

non-specific

3

10 times,
0.5% Triton-X

30

90 (tRNA)

1

non-specific

4

10 times,
0.5% Triton-X

30

90 (tRNA)

0.5

non-specific

2.2.2. Sequencing
For sequencing, DNA templates were prepared by colony PCR. Using an autoclaved
tip, random colonies were picked from a plate with ~100 colonies. The tip was then used
to streak a part of the plate, and dipped in 500 μL of ddH2O. The solution was used as
the DNA template solution for the colony PCR. In a 200 μL PCR tube, 1 master mix
along with the primers were added with the PCR reaction components. The Green Go
Taq master mix (2, Promega, Taq DNA polymerase, pH 8.5, 400 μM dNTPs, 3 mM
MgCl2) contains DNA polymerase, dNTPs, and buffers needed for the polymerase
reaction.
reagent

amount

DNA template
forward primer

2 μL
4 μL (5’-GCAAGCTGATAAACCGATACAAT-3’)

reverse primer

4 μL (5’-CCCTCATAGTTAGCGTAACG-3’)

Green Go Taq master mix

10 μL

The colony PCR reaction was performed using the following program. The PCR
protocol included a cycle for 1 min at 98 °C, 34 cycles for 10 sec at 98 °C (denaturing),
30 sec at 55 °C (annealing), 30 sec at 72 °C (extending), and 1 cycle for 5 min at 72 °C,
followed by holding at 4 °C. After the PCR cycles are done, the concentrations of the
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PCR products were measured using UV-vis spectroscopy (Nanodrop) at 260 nm. Then,
to confirm whether the PCR was successful with no contamination, the PCR samples
were run on a 2% agarose gel in 1  TBE buffer. Finally, the samples were diluted to a
concentration of 5 µg/µL, and sequenced.

Figure 2.5. A schematic representation of steps before sequencing is shown.

The sequences were found with colony PCR, followed by sequencing on the CEQ8000
(Beckman Coulter Inc., Pasadena, CA) in the RNA Instrument Room, Wayne State
University, and Illumina (San Diego, CA) in the DNA sequencing core, Wayne State
University. Except for the selections carried out at pH 5.5, from each of the selections
under varying conditions, 20 of the randomly picked colonies were sequenced and
aligned with ClustalW2 (EMBL-EBI, Cambridge, United Kingdom). For the selections
done at pH 5.5, 105 randomly picked colonies were sequenced and aligned.
2.3. Preparation of the peptides
Peptides were prepared by solid-phase synthesis.71 Rink amide AM resin, NovaSyn
TGR

resin,

Fmoc

(fluorenylmethyloxycarbonyl)-protected

amino

acids

and

O-

benzotriazole-N, N, N’, N’-tetramethyluronium hexafluorophosphate (HBTU) were
purchased from Novabiochem (Darmstadt, Germany). Diisopropylethylamine (DIPEA),
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dichloromethane (DCM), dimethylformamide (DMF), piperidine, trifluoroacetic acid (TFA),
thioanisole, triisopropylsilane (TIPS), ninhydrin, diethyl ether and acetonitrile (MeCN)
were purchased from Sigma-Aldrich (St. Louis, MO).
To Rink amide AM resin with a loading level of 0.68 mmol/g in DMF was added 20%
piperidine in DMF for deprotection, and mixed for 30 min. After confirmation of coupling
by a ninhydrin test, the mixture was washed with DMF and DCM (five times each). To
the Fmoc deprotected resin were added 2 eq. of Fmoc amino acid, 2 eq. of HBTU and 4
eq. of DIPEA, and the solution was mixed for 4 h. Again, the mixture was checked with
ninhydrin, and the resin was washed with DMF and DCM (five times each). These steps
were repeated for each Fmoc amino acid in the sequence. When the peptide of interest
was completed, the resin was dried and the peptide was cleaved with a cocktail of TFA:
thioanisole: TIPS: ddH₂O=94: 2: 2: 2 with 2 h incubation (Scheme 1.1). The cleaved
solution was precipitated and washed with cold ether, centrifuged at 5000 rpm for 30 min,
and after decanting, the white precipitate was dried in vacuo. The crude peptide was
then dissolved in ddH₂O and purified by HPLC (Luna C18 reverse phase column 250 ×
10.0 mm, 5 μm, Waters, Milford, MA) on a Waters 600 LC with a 717 autosampler
(Waters, Milford, MA, USA) and UV-detector by increasing the concentration of MeCN
from 0 to 40%. The fractions containing product peptide were lyophilized to give a white
powder. The peptide was then characterized by MALDI-TOF MS (Ultraflex, Bruker,
Billerica, MA). Positive mode on Ultraflex Extreme TOF/TOF from Bruker (Billerica, MA)
was used for detection, and 4-hydroxy-α-cyanocinnamic acid (Figure 2.1b) was used as
a matrix.
Branched peptides were prepared by solid-phase synthesis as described in the
previous section. However, the loading of Rink Amide AM resin is 0.68 mmol/g, which is
too high to synthesize branched peptides.132 Therefore, NovaSyn TGR resin with a
loading level of 0.31 mmol/g was used, which was purchased from Novabiochem
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(Darmstadt, Germany). Fmoc-Lys(Fmoc)-OH, Boc-Thr(Trt)-OH, and Fmoc-β-Ala-OH (B)
were purchased from Novabiochem (Darmstadt, Germany). Fmoc-propargylglycine-OH
and Fmoc-Lys(ivDde)-OH were purchased from Anaspec (Fremont, CA).

Figure 2.6. Structure of ivDde and the deprotection mechanism is shown. Hydrazine
removes the protecting group by forming a stable conjugated ring system via Michael
addition followed by cyclization, which cannot be performed with piperidine, and this
enables the branched peptide synthesis with different side chains.
Branches were formed using lysine, because both the backbone and side chain have
amino groups. For branched peptides with the same functional groups on each branch,
Fmoc-Lys(Fmoc)-OH was used for the synthesis. For branched peptides with different
peptides growing on each branch, Fmoc-Lys(ivDde)-OH was used.168 Both protecting
groups Fmoc and ivDde (Figure 2.6) are base-labile, but can be orthogonally
deprotected. Therefore, they are useful for asymmetric branched peptide synthesis. For
the

synthesis

of

mixed

peptides

with

different

branch

sequences,

(TARHIYBBB)(AAAAAABBB)-Lys-OH, TARHIYBBB was first added to the backbone
using Fmoc-protected amino acids except for threonine, where Boc-Thr(Trt)-OH was
added. Then, 5% hydrazine/DMF was added to remove the ivDde (1-(4,4-dimethyl-2,6dioxocyclohex-1-ylidene)isovaleryl) protecting group from the peptide, and the resulting
slurry was mixed for 30 min, followed by washing. Then, AAAAAABBB was added using
Fmoc-protected amino acids. The remaining steps, such as cleavage from the resin,
purification, and characterization were done the same way as described for the
monomer peptide.
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Figure 2.7. A general scheme for branched peptide synthesis is shown.
2.4. Fluorescent intercalator displacement (FID) assay
TO-PRO®-1 iodide solution (TOPRO, 3-methyl-2-((1-(3-trimethylammonio)propyl)-4quinolinylidene)methyl)benzothiazolium) was purchased from Thermo Fisher Scientific
(Waltham, MA). Potassium hydroxide (KOH) and HEPES were purchased from Fisher
Scientific (Hampton, NH). Magnesium chloride (MgCl2), sodium cacodylate, neomycin,
and paromomycin were purchased from Sigma-Aldrich (St. Louis, MO). For the FID
experiments, a Cary Eclipse Fluorescence Spectrophotometer (Varian, Inc., Walnut
Creek, CA) and Synergy H1 Hybrid reader (BioTek, Winooski, VT) were used to
measure fluorescence, with excitation at 500 nm and emission from 510 to 560 nm. To
the H69 RNA (1 μM) in buffer was added 1 eq. of TOPRO solution, and then the solution
was titrated with a ligand solution. TOPRO does not exhibit fluorescence in buffer, but
exhibits strong emission when bound to RNA.138 Each ligand was dissolved in 20 mM
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HEPES-KOH, 100 mM KCl, 5 mM MgCl2 (pH 7.0) buffer or 20 mM cacodylate, 100 mM
KCl (pH 5.5) buffer. The ligand samples were prepared at 0, 1, 10, 50, and 100 μM
concentrations. Each sample was mixed and incubated for 2 min before the
fluorescence measurement was done. For each experiment, negative controls were
done with buffer only, samples without H69, samples without TOPRO, and samples
without peptide. Each measurement was taken and the background spectrum was
subtracted. Each experiment was performed in triplicate. To calculate the relative
fluorescence, the fluorescence of the H69 and TOPRO in buffer before ligand addition
was determined (F0). Then, fluorescence from each sample was measured (F1 to Fn) and
the relative fluorescence was calculated by setting F0 to 1. The relative fluorescence
value for each sample was F/F0.
2.5. Electrospray ionization mass spectrometry (ESI-MS)
ESI-MS is a method used to obtain an apparent Kd value. This method has been used
previously for binding studies with RNA and various ligands.118, 120, 169 For most of my
studies, TriVersa nanospray with LTQ-XL from Advion (Ithaca, NY) was used in the
Proteomics Core under the direction of Paul Stemmer (Wayne State University). The
data were processed using Xcalibur (Thermo Fisher Scientific, Waltham, MA), and
analysis was done on GraphPad Prism (La Jolla, CA). Ammonium acetate (7.5 M,
NH4OAc) was purchased from Sigma-Aldrich (St. Louis, MO). In this study, the binding
was done at 10 mM NH4OAc in 50% isopropanol for both pH 5.5 and pH 7.0 conditions,
1 μM of H69 ΨΨΨ or H69 UUU, and the concentration of peptide varied from 0 to 100
μM. The salt concentration was lowered due to the limits of the instrumentation. The
samples were mixed and incubated for 10 min before ESI-MS analysis. Each titration
experiment was performed in triplicate.
Since RNA and peptides typically have different ionization efficiencies,147,

170

the

binding ratios were determined at different charge states and compared. To then
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determine relative Kd values, a single charge state was chosen for calculating binding
ratios for a single RNA species (e.g., UUU or ΨΨΨ) with closely related peptide ligands.
In this study of H69 and peptides, the binding ratios were determined from the peak
intensities at given m/z values for the (6-) charge state for free RNA and the complex.118,
169, 171

In other reports, the (5-) charge state was used because of stronger peak

intensities;118, 169 however, in this study we were not able to use the (5-) charge state
because the m/z of the RNA (1514) overlapped with the dimer peak of the peptide
(1514). Therefore, the (6-) charge state of the RNA and the peptide complex was used
for our studies. To compare the peptide binding to H69 ΨΨΨ and H69 UUU, the ratios of
the peak areas of free RNA, 1:1, and 1:2 complexes were determined.146, 170
The apparent dissociation constant of the RNA-peptide binding was obtained by
plotting the binding ratio to the peptide concentration. The data were plotted on
GraphPad, using nonlinear curve fitting with the quadratic equation (Equation 2.2). The
equation correlates the peak area for free RNA (R) and the RNA-peptide complex (RP),
with the titrated peptide concentration (P).
Equation 2.2.

2.6. Surface plasmon resonance (SPR) on BLItz
SPR is a method used to obtain an apparent Kd value along with kinetic data of binding
interactions. For these studies, the BLItz system and biosensors from ForteBio (Pall
ForteBio, Fremont, CA) were used. For the BLItz method, the biosensor was installed
onto the instrument and was soaked in the buffer for at least 10 min. The samples were
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prepared by serial dilution, and since the BLItz method is light dependent, the samples
were placed in black tubes to reduce background light. To the soaked biosensor was
loaded the target (i.e., biotinylated H69 ΨΨΨ or biotinylated H69 UUU) from a 5 μM RNA
solution onto the biosensor. The sample (ligand) solutions were prepared by serial
dilutions from 0, 0.7, 1.5, 3.1, 6.3, 13, 25, 50, to 100 μM in 20 mM HEPES-KOH, 100
mM KCl, 5 mM MgCl2 (pH 7.0) buffer or 20 mM cacodylate, 100 mM KCl (pH 5.5) buffer.
The cycles for ligand (peptide) binding included a baseline measurement in buffer for 30
s, association in ligand solution for 300 s, and dissociation in buffer for 300 s. For
biomolecular interactions, the response of the optical interference, kon, koff, and Kd values
were obtained. The experiments were performed in triplicate.
The apparent dissociation constant of the RNA-peptide binding was obtained by
plotting the binding ratio to the peptide concentration. The data were plotted on the BLItz,
using nonlinear curve fitting derived from Langmuir binding (Equation 2.3).
Equation 2.3.

2.7. Growth assay
To determine whether the phage selected have actual effects on E. coli survival, a
growth assay was performed.172-173 Custom-made phage were prepared by Antibody
Design Labs (San Diego, CA). As a negative control, SILPYPY, a known artifact
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sequence that was found in this study, as well as previous studies,119,

174

was also

prepared. The custom phage grows kanamycin in LB with 60 mg/L. ER2267, a strain
that is KanR, was obtained from New England Biolabs (Ipswich, MA) and used for the
growth assay.
To 100 mL of LB with 60 mg/L of kanamycin was added a single colony of ER2267,
which was allowed to grow at 37 °C overnight. The overnight culture was diluted 1:1000
times, then the phage of ~1010 virions/mL was added. After the phage was added, 2 mL
of the culture was withdrawn at 1, 3, 5, 7, 9, 11, and 24 h, then the OD600 was measured
on a Synergy H1 Hybrid reader (BioTek, Winooski, VT).
2.8. Nuclear magnetic resonance spectroscopy (NMR)
In this study, a 2D 1H homonuclear NMR experiment (2D COSY) was employed to
observe conformational changes of H69 upon binding. Potassium phosphate (KH2PO4)
and potassium chloride (KCl) were purchased from Sigma-Aldrich (St. Louis, MO),
99.96% deuterium oxide (D2O) was purchased from Cambridge isotope laboratories
(Tewksbury, MA), and ethylenediaminetetraacetic acid (EDTA) was purchased from
Fisher Scientific (Hampton, NH).
Solutions of H69 ΨΨΨ and H69 UUU (50 μM) in NMR buffer (20 mM KH2PO4, 100 mM
KCl, 1 mM EDTA, pH 5.5 or pH 7.0) were prepared, as well as solutions of H69 ΨΨΨ
and H69 UUU (50 μM) in the same buffer with peptide 10 times the apparent Kd, 500
μM). RNAs were renatured by heating the sample to 80 °C for 2 min then slowly cooling
to RT over 2 h. After renaturing, the respective peptides were added and allowed to
interact with the RNA for several hours at RT. NMR spectra were recorded using a
Bruker ADVANCE 700 MHz NMR (Billerica, MA) equipped with a TXI cryoprobe at 298K.
To determine structural effects of binding, ge-2D COSY was used to analyze JH5-H6 of the
pyrimidines. Peaks were assigned based off of previously reported values.47, 166
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CHAPTER 3 – SELECTION OF PEPTIDES BINDING TO H69 AT pH 5.5 USING
PHAGE DISPLAY AND BINDING STUDIES
3.1. Biopanning yield and diversity
Peptides targeting H69 ΨΨΨ at different conditions were selected after four rounds of
biopanning. In Table 3.1, the yield of each condition is shown. For tRNA, human H69,
H69 stem, and H69 UUU, the libraries were split after round 3. For rounds 1 and 2, the
library was incubated in 20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5%
glycerol, 0.1 mg/mL BSA with 0.1% (v/v) Tween-20 with 30 pmol of H69, and to that was
added 90 pmol of tRNAPhe as a competitor, which was removed after the incubation time
of 2 h. Starting with round 3, different competitors were used (Table 3.1), such as
human H69, H69 stem, and H69 UUU. For pH 5.5 (Table 3.1), the library was incubated
in 20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v)
Tween-20.
Table 3.1. Yield of each round of phage display with varying competitors.

round

tRNA (%)

1
0.078
2
0.035
3
0.003
4
8.0
‡
specific elution

human
H69 (%)
0.078
0.035
0.050
10

competitor RNA
H69 stem
H69 UUU
(%)
(%)
0.078
0.078
0.035
0.035
0.35
0.35
15
9.0

H69 UUU‡
(%)
0.078
0.035
0.5
5.0

pH 5.5 (%)
0.001
0.025
0.80
0.0005

The competitors in round 3 were chosen with the hope of finding a peptide that prefers
H69 ΨΨΨ over human H69, the H69 stem, or H69 UUU. Specific elution was performed
with H69 UUU. This experiment was designed to find a peptide that has binding towards
H69 in general, but preferred binding to H69 UUU. To increase the stringency, buffer
and wash conditions were changed for each step as described in Table 2.1.118, 120 The
concentration of detergent Triton-X increased from 0.1 to 0.5%, and the number of
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washes increased from three to ten times, and the incubation time decreased from 2 to
0.5 h.
Table 3.2. Diversity of each round of phage display
competitor RNA
round

tRNA

1.6 ˣ 108
1
5.5 ˣ 104
2
3
2
4
0
‡
specific elution

human
H69
1.6 ˣ 108
5.5 ˣ 104
27
3

H69 stem

H69 UUU

H69 UUU‡

pH 5.5

1.6 ˣ 108
5.5 ˣ 104
191
29

1.6 ˣ 108
5.5 ˣ 104
191
17

1.6 ˣ 108
5.5 ˣ 104
273
14

2.2 ˣ 106
5.5 ˣ 102
4
0

As described in Table 3.1, the yields from rounds 1 and 2 were 0.078 and 0.035%,
respectively. At round 3, for tRNA, the yield dropped to 0.003%. For tRNA, the increase
of number of washes and detergent with the decrease of incubation time led to a 10-fold
decrease in yield for non-specific elution. At round 4, an increase in yield was observed,
which is commonly seen in phage selection. The yield decrease followed by an increase
in biopanning can be explained with the fact that by round 3, the diversity of the library
decreased from >109 to <102 (Table 3.2). In this study, each round started with a plaque
forming unit (pfu) of 2 ˣ 1011, which has a diversity of about 1.3 ˣ 109. After the phage
were eluted, there was a step to amplify the phage so that the total number for the next
round was 2 ˣ 1011 pfu. At the first round, there were about 100 copies of each phage in
the library, and as more rounds are performed, the diversity decreased while the number
of each copy increased. Therefore, by the time the selection reached the 3rd or 4th round,
we estimated that there were less than 100 diverse sequences. The sequences
surviving all rounds succeed for various reasons. Some contain strong binding
sequences for the target, while others are fast growing phage, which amplify faster in the
E.coli host. The so-called fast growers were also reported in literature.

110, 175

Some

sequences are selected due to their ability to bind to plastic or streptavidinylated
magnetic beads, and these are called artifact sequences.176
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An increase in yield was observed when different competitors were added in round 3,
such as human H69, H69 stem, and H69 UUU. The yield for human H69 was 0.050%,
similar to rounds 1 and 2, and the yields for H69 stem and H69 UUU increased to 0.35%.
By round 4, the yields for biopanning done at pH 7.0 increased to 8-15%. This result
could be related to the diversity of the library (Table 3.2). The diversity dropped to less
than 30, and for pH 5.5 conditions or tRNA competitor, the diversity decreased to a
theoretical number of 0. Therefore, for the pH 5.5 selection, sequencing was performed
on the phage library from round 3. The low yield for the pH 5.5 selection could also be
due to the use of more acidic buffers, which have been reported to decrease the survival
of phage.121 As reported by Derda et al.,110 convergence to a few clones is shown in
more than 90% of phage display studies, although the drop of diversity leaves many
questions as to the validity of the phage selected. In biopanning, the target-phage library
incubation starts with >109 different phage, and after each round, the nonbinding phage
are washed out. After each round of selection, the phage are amplified so that incubation
of the library with the target is done with the same number of phage in each round.
However, this step may be the reason behind the convergence of sequences. Not all
phage have the same growth rate, and therefore, fast-growing phage that do not
necessarily bind to the target may be amplified during this step. There is a possibility of
selecting fast-growing peptides over strong binders. This leads to the conclusion that the
relative abundance of sequences may not necessarily correlate to the binding affinity,
which has been shown in previous studies by Abdeen et al.177 To overcome the loss of
diversity, use of an unamplified library could be considered, but then the ratio of phage
to target would be needed to be considered.
3.2. Peptide sequence analysis
In the first set of conditions used, to check the effect of differing competitors, several
RNAs such as the stem region of H69, human H69, and tRNAPhe were added. The
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phage library was incubated in pH 7.0 binding buffer (20 mM HEPES, 100 mM KCl, 5
mM MgCl2, 5% glycerol, 0.1 mg/mL BSA) and competitors, followed by washing and
non-specific elution with acidic glycine buffer. After four rounds of selection, 20 randomly
picked colonies of each condition were sequenced. The selection conditions are
displayed in Table 2.1.

Figure 3.1. Sequences from randomly picked colonies from the selection with
competitors human H69, H69 stem, and H69 UUU at pH 7.0 are shown. The upper
part of the panel displays the sequence of the RNA competitors. The middle part with
WebLogo 3.3 shows the consensus of the peptide sequences selected, in which the
size of the sequence shows the frequency of the sequence appearing. The sequences
of the peptides are aligned on the lower part of the panel.
For all selections, we were able to observe a sequence that shows up more frequently
than others, FGHYHYA. However, this sequence also appeared frequently in the
negative control experiment, in which tRNAPhe was used as a competitor with H69 ΨΨΨ
as a target. From round 3, different competitors were used (Table 3.1), such as human
H69, the H69 stem, and H69 UUU. These competitors were selected to find a peptide
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that prefers H69 ΨΨΨ over human H69, H69 stem, or H69 UUU. Peptide SHSLLHH
appeared three times when human H69 was used as the competitor. The sequence
SFVLPYY appeared four times when the stem region was used as a competitor. The
sequence SPPHHND appeared three times when H69 UUU was used as a competitor
(Figure 3.1). However, the selectivity of the peptides obtained was questionable. If the
sequence prefers to bind to H69 UUU over H69 ΨΨΨ, the sequence would be expected
to appear with the specific elution with UUU, not when H69 UUU was used as a
competitor. These results imply that the sequences may bind to the loop region of the
target H69.
For specific elution with UUU, six different sequences were obtained. Sequence
FGHYHYA appeared 12 times, while FAPYNHA, WATQHWA, WPTLQWA, LASHTAP,
and KILGWSG were each observed once. In this case, the main peptide was FGHYHYA,
which was also found in the selections at pH 7.0 with differing competitors as described
above. Unfortunately, this sequence may be a fast grower and lacking selectivity for H69.
Therefore, the sequences screened in this study were most likely fast-growing phage,
which could also explain the presence SILPYPY, another sequence reported in the
literature as a fast-grower.110, 119 For these reasons, we did not pursue further studies
with these sequences.
In the 4th round, the yield was >5% for the non-specific elution conditions at pH 7.0.
For the selection at pH 5.5, the yield was still very low (0.0005%) after the 4th round, but
a consensus was still obtained from the sequence alignment (Figure 3.2). The poor yield
may be a result of amplification of sequences that are harmful to the host bacteria. While
performing biopanning, there is a possibility of target-unrelated sequences being
selected. Among the phage, some of them are prone to propagate faster than others,
which would lead to their selection. Therefore, the peptide sequences were checked with
the literature and SAROTUP, a program that searches for target-unrelated peptides
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developed by Huang et al.176 Among the sequences shown, none of them are known for
binding to streptavidin or to be target-unrelated peptides.176 However, three sequences,
SAPHHND, SPPHHND, and SRAHHIA, turned out to be fast-growing peptides. Also,
sequences SILPYPY and HAIYPRH were reported previously to be artifact
sequences.110, 119

Figure 3.2. Sequences selected at pH 5.5 were aligned. Compared to sequences
screened under pH 7.0 conditions, these sequences contained more polar residues.

In the third set of conditions, when the buffer conditions were altered, we observed
some differences in the selected peptides. Previous work showed that the H69
conformation changes with the Mg2+ concentration.66-67, 178 To determine whether there
are different sequences screened under differing Mg2+ concentrations or pH conditions,
phage display was conducted at pH 5.5 in PBS. After four rounds, 105 randomly picked
colonies from each condition were sequenced. The conditions are displayed in Table 2.3.
The sequences from the pH 5.5 selection showed a consensus. The sequences were
sorted, as shown in Figure 3.2. Peptides SILPYPY, SAPHHND, and SHSLLHH that
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were observed in higher pH buffer selections appeared three, three, and one time(s),
respectively. The sequence FGHYHYA that appeared in pH 7.0 buffer conditions was
not found in this selection. TPARHIY appeared 38 times out of 105 sequences.
Table 3.3. Sequences selected for further studies176

Overall, from the sequence analysis we cannot determine whether the goal to find
phage that selectively bind to H69 in a closed conformation was achieved or not.
However, the sequence TPARHIY that appeared 38 times was only observed from pH
5.5 selections (Figure 3.2). For further studies, peptides in Table 3.3 were chosen
based on the selections done at pH 5.5 buffer conditions, and the alignments in Figure
3.2, with at least one sequence from each family. Also, if the selected peptides were also
found under pH 7.0 buffer conditions, they are listed in Table 3.3. These peptides are
unlikely to have selectivity for H69 ΨΨΨ over H69 UUU, but may have potential binding
to either form of H69.
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3.3. Preparation of RNA
The RNAs H69 ΨΨΨ and H69 UUU were prepared as mentioned in Section 2.1. In
Figure 3.3a, the 20% polyacrylamide gel is shown after purification and desalting of the
RNAs, which was also verified by MALDI-TOF (Figure 3.3b).

Figure 3.3. Representative data of purified H69 ΨΨΨ and H69 UUU are shown. a)
Isolated H69 on a 20% polyacrylamide gel is shown. b) The MALDI-TOF spectrum of a
purified H69 ΨΨΨ is given. The predicted mass of H69 (M+H)+ is 6060.7 Da.
3.4. Preparation of peptides
Selected peptides were synthesized using solid phase peptide synthesis as
described in Section 2.5. The structures of the peptides are shown in Figure 3.4.
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Figure 3.4. Structures of the amidated peptides used in this thesis work are shown
(with protonation states at pH 7.0). The peptides are all positively charged.
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The sequences display positive charges at both pH 5.5 and pH 7.0 conditions. In
comparison to previous selections that found neutral and positively charged
peptides,118-120 these peptide sequences contain amino acids with more charges or
greater hydrophilicity. Out of 14 peptides in Figure 3.4, 10 of them contain one or
more histidines, which is neutral at pH 7.0 and positively charged at pH 5.5. This
may have resulted from the selection being carried out at lower pH and the target
being a negatively charged RNA, which attracts the positively charged peptides.

Figure 3.5. The MALDI-TOF spectrum (a) and HPLC trace (b) of purified TARHIY are
shown. The other peptides are displayed in Appendix A.
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During the synthesis, peptide TARHIY (Figure 3.5) was also obtained in addition to
TPARHIY (Figure 3.4b). Since proline has a secondary amino group, it is difficult to
tell from a Kaiser test179 if it has been incorporated into the peptide (Figure 3.6). The
major peptide product was shorter than the heptamer peptide screened from phage
display, which happens to make it more druggable according to literature precedence
with small peptide drugs.180 Therefore, the TARHIY peptide was used for subsequent
binding and biological experiments. The peptides were HPLC purified and
characterized by MALDI-TOF.

Figure 3.6 Kaiser test with primary and secondary amino acids is shown.179

3.5. Screening peptides with the FID assay
The FID assay was performed under buffer conditions that were used previously.138
The dye, TOPRO, bound to H69 and demonstrated increased fluorescence upon
interaction with the RNA. If a ligand displaces the dye, the fluorescence is then expected
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to decrease. The change in fluorescence can be therefore used to estimate relative
binding affinities of ligands to RNA. The concentration of the ligands varied from 0 to 100
μM. In this study, displacement of fluorescence was determined by the addition of
neomycin as a control, and then the selected peptides with H69 UUU or H69 ΨΨΨ were
tested. There was little dye displacement by most of the peptides (less than 5%). The
low change in fluorescence upon addition of peptide to the TOPRO-RNA complex was
noticeably different from the response with neomycin, a known H69 binder. The
fluorescence decrease observed with neomycin titration was consistent with results from
previous studies employing 2-aminopurine-incorporated H69.67 The lack of fluorescence
change can be interpreted as a lack of peptide binding, or another mechanism such as
peptide binding to the complex without dye release, or peptide binding to the dye alone.
Some of the peptides, such as TARHIY, TPARHIY, SHSLLHH, and RQVANHQ
exhibited some displacement at higher concentrations (>50 μM) (Figure 3.7). The
displacement was most apparent when the ratio of [RNA]:[TOPRO] was 1:1.
Interestingly, however, the shortened peptide TARHIY, showed greater displacement of
TOPRO than the phage-selected peptide TPARHIY. TARHIY showed displacement of
TOPRO up to 28% at 100 µM.
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Figure 3.7. FID assay of peptides against H69 ΨΨΨ and H69 UUU at pH 5.5 and pH
7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl buffer was used. For pH
5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer was used. The assay was
performed in triplicate (1:1 ratio of RNA:TOPRO, 1 µM each).
The specificity of TARHIY towards H69 was examined by carrying out the binding
experiment with tRNAPhe. Neomycin was also used as a control, because it is known to
bind to tRNAPhe. Displacement of fluorescence by the addition of neomycin at both pH
7.0 (Figures 3.8b and 3.8c) and pH 5.5 (Figure 3.8d and 3.8e) conditions, with either
100 mM KCl present (Figures 3.8c and 3.8e) or none (Figures 3.8b and 3.8d). Salt in
physiological buffers play an important role in RNA structures and interactions; therefore,
binding events of the peptide or neomycin to tRNAPhe in varying ionic strengths was
examined. Both Mg2+ and K+ play important roles, however, only the concentration of K+
was varied in this study because Mg2+ is reported to play important roles in RNA
folding.181 The dye TOPRO is reported to interact with bulges of RNA, therefore,
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maintaining the folded structure is important in this assay.138, 182 For the same reason,
although no Mg2+ was present in the phage selection at pH 5.5, buffers used at both pH
5.5 and pH 7.0 contained Mg2+.

Figure 3.8. Salt dependence of neomycin and TARHIY against tRNAPhe at pH 5.5 and
pH 7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl buffer was used, and
for pH 5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer was used, wherein
less salt (b and d) conditions indicate no potassium and regular salt (c and e)
conditions indicate 100 mM KCl. The assay was performed in triplicate (1:1 ratio of
RNA:TOPRO, 1 µM each). a) The structure of tRNAPhe is shown. b-e) Results of the
FID assay with neomycin and TARHIY in the presence of tRNAPhe are shown.
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At higher concentrations of the ligands (>50 µM), the salt concentration made little
difference (<3%) in displacement of dye at both pH values. At pH 7.0, neomycin
exhibited a 1.5-fold lower change of fluorescence compared to studies done at pH 5.5,
suggesting less binding to the RNA. At lower concentrations of neomycin (1 and 10 µM),
less binding to tRNA was observed when either the salt concentration or pH were raised
(up to 20%). The impact of salt on neomycin binding to tRNAPhe is not surprising given
that the binding mode involves electrostatic interactions. Unlike neomycin, in less salt
conditions without K+ ions present, TARHIY showed little dye displacement (<5%
decrease in fluorescence at 100 µM) with addition of the peptide (Figure 3.9), and no
significant preference for buffer conditions. However, with 100 mM KCl present, upon
TARHIY titration at 50 and 100 μM, the dye displacement would increase up to 20 and
28%, respectively. The difference caused by the presence of K+ may be due to the salt
playing an important role in folding of the RNA, wherein K+ may stabilize specific RNA
structures. This may also provide some information on the binding mode of the peptide.
If the peptide binds to H69 through an electrostatic manner, the structure of H69 would
be sensitive upon binding of the peptide that would change the secondary structure. This
assay is based on TOPRO interacting with the RNA in a certain secondary structure,
and if the structure is too flexible, addition of peptide may not impact the structure and
cause TOPRO displacement. If the structure is rigid, addition of peptide would be
expected to cause displacement of the dye.
A salt dependence study was also performed with H69 ΨΨΨ and H69 UUU (Figure
3.9). The salt concentration may impact ligand interactions either directly or indirectly
(i.e., RNA structural changes may affect ligand binding). In the absence of potassium,
the dye displacement was enhanced with neomycin at all concentrations (up to 25%),
but not with TARHIY for both H69 constructs at lower ligand concentrations (<50 µM).
The results for neomycin and H69 were consistent with the results for tRNAPhe. For
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TARHIY, fluorescence quenching was only observed at higher concentrations of the
peptide (50 and 100 µM, up to 18%).
A pH dependence study was also performed with H69 ΨΨΨ and H69 UUU (Figure
3.9). At pH 5.5, 2-fold enhancement in dye displacement was observed with neomycin
(at all concentrations) and TARHIY (at higher concentrations, 50 and 100 µM) compared
to pH 7.0. However, no preference for H69 type was observed. At higher concentrations
of the peptide (50 and 100 µM, up to 18%) at pH 5.5 conditions, a minor difference was
observed upon TARHIY binding. The phage selection was done at pH 5.5 with no Mg2+,
so the conditions of this assay were different (5 mM Mg2+). We hoped to find a peptide
that preferred the closed-conformation, and at pH 5.5, the absence of Mg2+ was reported
to favor this conformation.67 The presence of Mg2+ in this assay may have induced a
mixed conformation, resulting in only a small difference between the pH conditions.
However, although the peptide did not show selectivity between H69 ΨΨΨ and H69 UUU,
a very modest selectivity of H69 over tRNAPhe can be observed if the data in Figures 3.8
and 3.9 are compared. Lastly, the peptide caused little fluorescence change (up to 28%
at 100 µM), while neomycin showed displacement up to 90% at 100 µM.
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Figure 3.9. Salt dependence of neomycin and TARHIY against H69 ΨΨΨ and H69
UUU at pH 5.5 and pH 7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl
buffer was used, and for pH 5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer
was used, wherein less salt (b and d) conditions indicate no potassium and regular salt
(c and e) conditions indicate 100 mM KCl. The assay was performed in triplicate (1:1
ratio of RNA:TOPRO, 1 µM each).
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3.6. Binding studies with ESI-MS
The goal of ESI-MS experiments was to determine the binding affinity and selectivity of
the peptide TARHIY towards H69 ΨΨΨ and H69 UUU at differing buffer conditions (i.e.,
varying pH), and obtain apparent Kd values and stoichiometries. Previous studies have
shown that ESI-MS is a method useful to obtain apparent Kd values for peptide-RNA
complexes.118, 120, 169 The dissociation constant obtained from this study is relative, not
absolute, due to the ionization efficiencies being different between RNA and peptide.
Furthermore, the decrease of free RNA was not directly related to the increase of the
RNA-peptide complex formation (Figures 3.10 to 3.13), because the (4-) charge state
for the RNA overlapped with the dimer peak of the peptide. In this thesis work, the
binding was measured at 10 mM NH4OAc for both pH 5.5 and pH 7.0 conditions, which
is lower than the salt concentration used for selection. The salt concentration employed
was lower due to the instrumentation limits; however, the data quality was still poor due
to background salt in the samples, which is more apparent in low salt buffers. Despite
much effort to purify them, the peptide samples contained residual salt after HPLC. Each
experiment was performed in triplicate.
Since the RNA and peptides have different ionization efficiencies, the binding ratios
were different for each condition tested. Therefore, conditions were carefully controlled
in order to compare and get relative binding information for different RNAs or peptides.
The binding ratio was calculated by comparing the (5-) charge states for both RNA and
complex. Although the (4-) charge state of H69 showed a stronger signal than other
charge states, we were not able to focus on this charge state because it matched the
dimer peak of the peptide (Figures 3.10 to 3.13). Therefore, the (5-) charge state of the
RNA and the complex were used for these studies to determine the peak areas and
relative free and bound concentrations.
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Figure 3.10. Representative ESI-MS results for TARHIY titration at pH 5.5 against H69
ΨΨΨ are shown. In the spectra, complexes of 1:1 and 1:2 (H69 ΨΨΨ:peptide) binding
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc
(pH 5.5).
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Figure 3.11. Representative ESI-MS results for TARHIY titration at pH 5.5 against H69
UUU are shown. In the spectra, complexes of 1:1 and 1:2 (H69 UUU:peptide) binding
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc
(pH 5.5).
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Figure 3.12. Representative ESI-MS results for TARHIY titration at pH 7.0 against H69
ΨΨΨ are shown. In the spectra, complexes of 1:1 and 1:2 (H69 ΨΨΨ:peptide) binding
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc
(pH 7.0).
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Figure 3.13. Representative ESI-MS results for TARHIY titration at pH 7.0 against H69
UUU are shown. In the spectra, complexes of 1:1 and 1:2 (H69 UUU:peptide) binding
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc
(pH 7.0).
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The apparent Kd values as given in Table 3.4 were obtained using the quadratic
equation. The fraction of RNA-peptide complex to free RNA was plotted using GraphPad
(Figure 3.14). The RNA-peptide complex did not reach saturation most likely because
the ionization efficiencies of the RNA-peptide complexes are much lower than that of the
free RNA. Despite these limitations, we could gain knowledge about relative binding
affinities. The peptides showed moderate (low μM) binding to both H69 ΨΨΨ and H69
UUU. As with the FID studies, no significant selectivity between the modified and
unmodified RNA was observed. Although the binding affinity (μM) of the peptide to RNA
may appear low compared to protein-drug interactions (nM), it should be pointed out that
aminoglycosides, which are effective ribosome-targeting antibiotics, bind with similar
affinity to rRNA (low μM) and with very poor selectivity.
When the titrated peptide concentration exceeded 20 μM, a complex of peptide dimer
bound to RNA was detected, which may imply an aggregation or more than one binding
site of the peptide. These results led to studies of multimeric peptide binding studies with
H69 (Chapter 4).
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Figure 3.14. ESI-MS results for TARHIY at 10 mM NH4OAc (pH 5.5 and pH 7.0)
against H69 ΨΨΨ and H69 UUU. a) The titration curves for TARHIY bound to H69
ΨΨΨ and H69 UUU (y axis: binding ratio of at (5-) charge state) at different buffer
conditions (pH 5.5 vs. pH 7.0) are shown.

Table 3.4. Apparent dissociation constants (Kds) obtained from ESI-MS. The apparent
dissociation constants (Kd values) were obtained by fitting relative binding ratios with a
quadratic equation.
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3.7. Binding studies with SPR
SPR is a method used to obtain apparent Kd values in solution phase by monitoring
interactions of the surface of a CM5 chip.183 This method does not need a tag on the
peptide, and the binding event is detected by monitoring the change in response unit.
The response unit is derived from alteration of the refractive index of the chip upon
binding. To a CM5 chip was immobilized streptavidin, followed by immobilization of
biotinylated H69 ΨΨΨ. To reduce nonspecific binding after immobilization of the
biotinylated H69 ΨΨΨ, biotin was passed through the cells to coat any exposed
streptavidin sites. Following H69 immobilization, the TARHIY concentration was varied
from 0 to 100 μM in both pH 5.5 (20 mM PBS, 100 mM KCl) and pH 7.0 (20 mM HEPES,
100 mM KCl, 5 mM MgCl2) buffers. Each experiment was performed in triplicate. Since
the mass of the peptide (758 Da) was smaller compared to H69 (6060 Da), the response
unit change was small, but significant. This was the first time in our laboratory that we
were able to monitor peptide binding to H69 using SPR. However, the signal was only
detectable under pH 5.5 conditions, possibly due to nonspecific charge-charge
interactions between the positively charged peptide (pI=9) and negatively charged
streptavidin (pI=5) under pH 7.0 conditions. In Figure 3.15, curves obtained from
streptavidinylated surfaces exhibit a sharp increase immediately after injection followed
by a flat line, while curves obtained from avidinylated surfaces exhibit a more gradual
increase following the initial injection. Avidin (pI=10.5) was used instead of streptavidin in
an attempt to detect binding at pH 7.0, but was unsuccessful (Figure 3.15). A binding
affinity of 27 µM was obtained with streptavidinylated surfaces, and 11 µM with
avidinylated surfaces (2.5-fold tighter binding). Although the phage were selected using
streptavidinylated magnetic beads, the Kd value obtained with avidinylated surfaces (11
µM) matched more closely with the Kd value obtained with ESI-MS (10 ± 2 µM).
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Figure 3.15. SPR results for TARHIY at pH 5.5 (20 mM cacodylate, 100 mM KCl, and
0.1% Tween-20) against H69 ΨΨΨ with a) streptavidin or b) avidin. The curves shown in
color correspond to measurements of a two-fold serial dilution of the peptide ligands
over a concentration range. The curves in black correspond to global fits in 1:1 binding
model (R2>0.88).
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The kinetics of the binding events with streptavidin or avidin revealed difference
between the two proteins immobilized to the CM5 chip. For streptavidin, kon of 4.2e3 Ms-1
and koff of 2.7e-5 s-1 values were obtained, compared to kon of 13 Ms-1 and koff of 0.02 s-1
for avidin. A higher kon was observed with streptavidin, implying a fast nonspecific
charge-charge binding interaction of the peptide to H69. The apparent binding affinities
obtained from kon and koff appeared to be unusually high or low (6.4 nM for streptavidin
and 1.4 mM for avidin). Furthermore, poor fitting was observed in both cases, implying
that the binding of TARHIY to H69 is not through 1:1 binding.
3.8. Binding studies with BLItz
The goal of BLItz studies was to determine the binding affinities of peptide TARHIY to
H69 in pH 5.5 and pH 7.0 buffer conditions and compare to other methods. Similar to
SPR, this method is useful for monitoring binding events in situ, and can be used to
obtain kinetic information as well as determining the binding constants.
Previous studies have shown that BLItz results correlate with SPR,162 likely because of
the similar detection method. One major difference between BLItz and SPR is the mode
of association and dissociation. SPR has the biosensor immobilized onto a chip and
there are flow channels that the ligands and analytes flow through. Therefore, for
association and dissociation, a buffer solution containing a target or ligand is constantly
flowing over the chip. This process may cause mass transport, but the concentration of
the solution stays constant during the process. BLItz uses a biosensor that is
immobilized onto a tip that is dipped into a tube containing a buffer solution with a target
or ligand. The instrument is designed to constantly shake the tube so that the solution
around the biosensor is not just monitoring diffusion.162, 184 Association and dissociation
in this method is done in the same solution into which the biosensor is dipped, with
concentrations of the target or ligand increasing or decreasing manually. Therefore, for
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binding studies with molecules sensitive to the concentration, it is necessary to use large
volumes (250-300 µL) of the solution of interest to minimize error.
In Figure 3.16, binding curves obtained from BLItz and dissociation constants are
shown. The peptide ligand, which has a mass of 1/8th of the immobilized RNA, produced
a small change in signal in SPR. With the use of BLItz, the change in signal was more
apparent, as shown in Figure 3.16. (Expanded figures are displayed in Appendix B)

Figure 3.16. BLItz binding curves for TARHIY at pH 5.5 (20 mM cacodylate, 100 mM
KCl, and 0.1% Tween-20) and pH 7.0 (20 mM HEPES-KOH, 100 mM KCl, 5 mM
MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and H69 UUU. The curves shown in
color correspond to measurements of a two-fold serial dilution of the peptide ligands
over a concentration range of 0 to 100 μM. The curves in black correspond to global
fits in 1:1 binding model. The experiments were performed in triplicate. The expanded
figures are displayed in Appendix B.
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Examining the kinetics of the binding events revealed similar kon and koff values for
TARHIY binding to H69 ΨΨΨ and H69 UUU at pH 5.5 and pH 7.0. The average kon and
koff values are given in Table 3.5. In these cases, poor fitting and large errors were
observed, both by the sensogram (Figure 3.16 and Appendix B) and the rate constants
(Table 3.5), implying that the binding of TARHIY to H69 is probably not through a simple
1:1 binding mode.
Table 3.5. Rate constants (kon and koff) obtained from BLItz

The apparent dissociation constants obtained from BLItz are reported in Table 3.6.
The apparent dissociation constants were ~15 µM, which did not show a significant
preference for RNA type or pH value. The binding affinities obtained with this method in
physiological buffers, which were used in the phage selection, agree well with the data
from ESI-MS. As mentioned earlier these values also demonstrate moderate affinity of
the peptide for H69, which matches that of some natural antibiotics that target H69.
Table 3.6. Apparent dissociation constants (Kds) obtained from BLItz

3.9. NMR spectroscopy
In this study, 2D 1H homonuclear NMR experiments (2D gCOSY) were employed to
examine the binding of TARHIY to H69. Crosspeaks between the H5-H6 protons on the
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pyrimidines of H69 were observed. If the ligand binds to H69, the local chemical
environments of nuclei on H69 may be altered by the ligand directly if it binds in
proximity or changes the local H69 RNA conformation upon titration with peptide.
Overlays of NMR spectra of H69 obtained with TARHIY are shown in Figures 3.17 to
3.19.

Figure 3.17. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of TARHIY at pH 5.5. The concentrations of RNA and peptide were 50
and 500 μM, respectively. The arrow indicates the chemical shift change and direction
at C1914. The NMR spectra were obtained by Evan Jones.
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Figure 3.18. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or
presence (grey) of TARHIY at pH 5.5. The concentrations of RNA and peptide were 50
and 500 μM, respectively. The arrow indicates the chemical shift change and direction
at C1914. The NMR spectra were obtained by Evan Jones.

Figure 3.19. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of TARHIY at pH 7.0. The concentrations of RNA and peptide were 50
and 500 μM, respectively. The arrow indicates the chemical shift change and direction
at C1914.The NMR spectra were obtained by Evan Jones.
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Upon addition of TARHIY at pH 5.5 conditions, changes in the chemical shifts were
observed at C1914 (Figure 3.17) and C1920 (Figure 3.18) for H69 ΨΨΨ and H69 UUU,
respectively. The chemical shift change in H69 UUU at C1914 and U1915 was less than
0.02 ppm (Figure 3.17), whereas the change at C1920 for H69 ΨΨΨ was ~0.04 ppm.
For H69 ΨΨΨ at pH 5.5, the C1914 crosspeak was not detected, possibly due to
structural dynamics (Figure 3.18). The changes upon peptide binding imply alterations
in the chemical environment around those residues. Residue C1914 is located in the
loop region of H69, and C1920 is at the stem-loop transition region. The results imply a
direct interaction with TARHIY or an induced conformation change at these regions due
to peptide binding. Residue C1914 was shown in previous studies to participate in base
stacking with Ψ1915.48, 185 This is the first time that we observed interactions in the loop
region of H69 by a small molecule. Previous studies with DMS probing suggested that
the RNA structure involves A1913 existing in a stacked-in

(less solvent exposed)

conformation at lower pH (pH 5.5) and lower Mg2+ concentrations (1 mM).178 The buffer
conditions for the selection experiment was at pH 5.5 with no Mg2+ (20 mM KH2PO4, 100
mM KCl, 1 mM EDTA, pH 5.5 or pH 7.0).178 The concentrations of RNA and peptide
were 50 and 500 µM, respectively.
The spectrum of H69 UUU with TARHIY at pH 7.0 is shown in Figure 3.19. No change
in the chemical shifts were observed in this case. The binding studies discussed in
previous sections revealed that there was no apparent difference in binding affinity to
H69 ΨΨΨ or H69 UUU regardless of the solution pH. The NMR results suggest that
binding of the peptide to H69 UUU at pH 7.0 changes the local RNA conformation which
was not observed for H69 ΨΨΨ. From previous studies, it was shown that a decrease in
the pH value may induce increased stacking of the loop region in H69 ΨΨΨ.67, 178 The
peptide may bind to the loop, but the stacking interactions may not be impacted enough
to observe a change in the NMR spectrum.
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3.10. Growth assay
To determine whether the selected phage have effects on survival of E. coli, a growth
assay was performed. Custom phage displaying peptides TARHIY and TPARHIY were
prepared to determine whether there is a difference between the two sequences with
respect to bacterial growth. A known artifact sequence SILPYPY, which was found in
this study and previous studies, was used as a negative control.175 The custom phage is
KanR, and since kanamycin does not interfere with H69 function, the growth was
predicted to be dependent on the phage present. The custom phage were grown with
kanamycin at 60 mg/L in LB media. The bacterial strain ER2738 used for phage display
was TetR, therefore the custom phage would not grow in ER2738. Instead, ER2267, a
phage strain that is KanR, was used for the growth assay.
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Figure 3.20. Growth assay results are shown. To media containing ER2267, ~1010
virions of phage were added and their effect on growth was monitored. Values are
average values of three measurements. Except for the measurement with SILPYPY
(18% error) at 24 h, each measurement exhibited a small difference (<3%). The data
were fitted with GraphPad.
The goal of this assay was to examine growth impact of the selected phage. The
selected phage (TARHIY) reduce the growth at 24 h by 40% compared to the control
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with no phage infection. However, for the other phage studied (TARHIY, TPARHIY,
HITSTRY, and SILPYPY), a decrease (<20% at 24 h) in growth was observed. At 24 h,
compared to SILPYPY, a peptide that was selected in previous studies to be a fast
grower, peptides TPARHIY and TARHIY showed 20% decrease in growth. Compared to
HITSTRY, another peptide that was selected during this selection, peptides TPARHIY
and TARHIY showed 10% decrease in growth. However, the difference was not
significant, and no phage showed more than 40% decrease in growth, which may reveal
some information of the selected phage. As discussed in Sections 3.1 and 3.2, the
phages selected through phage display may be fast growers in general, because phage
causing complete growth inhibition would never be selected. The phage encoding
TARHIY and TPARHIY showed similar growth, implying that the proline may not impact
the peptide activity. The TPARHIY peptide was selected from phage display and
appeared 38 times out of 105 sequences, indicating that it overpowered other fastgrowing phage. In contrast, the TARHIY peptide was discovered through the binding
analysis following selection. Nonetheless, they appear to have similar activity in the
growth assay.
3.11. Competition studies of peptide TARHIY and neomycin to H69 using BLItz
Previous studies have shown that neomycin interacts with the stem region of H69. 186187

For ribosome recycling, RRF interacts with H69, which then separates H69 from

forming B2a intersubunit of the 70S ribosome.32, 61, 186, 188 Rings I and II of neomycin was
shown to be bound to H69 at residues G1921-C1924 and G1906 (Figure 3.21), which
alters the conformation of H69.186 The interaction between H69 and RRF was shown to
be disrupted upon binding of 2-DOS, leading to inhibition of ribosome recycling.186
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Figure 3.21. A chemical structure of neomycin and crystal structure (PDB ID: 4V52) of
H69 and neomycin is shown.

In previous sections, a peptide TARHIY was derived from a sequence selected from
phage display, which exhibited a moderate binding to the loop region of H69. Through
ESI-MS and BLItz, the peptide exhibited moderate binding to H69. A Scatchard analysis
of ESI-MS data implied there is cooperative binding of the peptides to H69. The primary
binding site was the H69 loop region. Therefore, peptide TARHIY binding to H69 in the
presence of neomycin was explored. The peptide, TARHIY was shown to have binding
to the loop region of H69, while neomycin was shown in previous studies to bind to the
stem region of H69, so we were curious to know if both ligands could bind
simultaneously to H69.
3.11.1. Design of binding assay of neomycin and TARHIY to H69 using BLItz
In previous chapters, biotinylated H69 was immobilized to a streptavidinylated surface
to select peptide ligands and to monitor the binding of ligands, such as monomer
peptides or dimeric peptides in buffer, using SPR or BLItz. However, to monitor dual
binding of neomycin and peptide TARHIY, immobilization of the RNA followed by binding
of ligands (neomycin or peptide TARHIY) may not be able to show dual binding modes.
Therefore, to monitor dual binding of neomycin and peptide TARHIY to H69, instead of
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immobilizing the target, H69, a biotinylated peptide TARHIY was immobilized onto the tip,
followed by association of free H69. After the H69 association step, we monitored the
biosensor in a secondary association step in buffer, then solutions containing neomycin
or peptide TARHIY, or the free RNA (Figure 3.22).

Figure 3.22. A schematic design of a BLItz experiment to monitor dual binding of
peptide and neomycin to H69 is shown. a) Sensor preparation with peptide
immobilization is illustrated. b) The first association of H69 is represented. c) The
second association of neomycin is shown. d) A schematic sensogram of steps a) to c)
is shown.

To immobilize the peptide onto a streptavidinylated biosensor, a biotinylated peptide
TARHIY was synthesized. A schematic description of the synthesis is shown in Scheme
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3.1. By utilizing a orthogonally protected Fmoc-Lys(ivDde)-OH, peptide TARHIY was
synthesized onto the α-amino group, followed by attachment of biotin onto the ε-amino
group. The peptide was then cleaved with a cleavage cocktail described in Chapter 2,
followed by purification with HPLC. The structure and MALDI-TOF spectrum of the
purified biotinylated peptide TARHIY is shown in Figure 3.23.
Scheme 3.1. Scheme of synthesis of biotinylated peptide TARHIY
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Figure 3.23. MALDI-TOF spectrum of biotinylated peptide TARHIY is shown.

3.11.2. Binding of neomycin and TARHIY to H69 using BLItz
To monitor possible dual binding of neomycin and TARHIY to H69, BLItz was used. To
a streptavidinylated sensor, biotinylated peptide TARHIY (Bi-TARHIY) was immobilized,
followed by binding events at pH 5.5. The RNA H69 UUU (1 μM) in 20 mM PBS, 100 KCl
was then added, followed by incubation with buffer, neomycin (1 μM), or free peptide
TARHIY (10 μM) in buffer. The concentration of neomycin solution and peptide TARHIY
was based on the Kds observed in previous studies. The sensogram is shown in Figure
3.24. In theory, if the binding sites of neomycin and peptide TARHIY are independent
from each other, one would expect to see a sensogram such as Figure 3.24b, which
shows increase in signal when neomycin binds, and decrease in signal in buffer.
However, the buffer showed similar dissociation curve compared to the free peptide,
while neomycin showed a steep decrease in dissociation. This result indicates that
although the primary binding sites are different, the binding modes of the two molecules
to H69 UUU are not independent. In this case, neomycin and TARHIY appear to have
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competitive binding to H69, or allosteric binding of one ligand impacts binding by the
second ligand.

Figure 3.24. BLItz sensogram and table indicating each step incubation of peptide
biotinylated TARHIY, RNA H69 UUU, and neomycin are shown. a) Overlay of
sensograms are shown. b) A description of each sensogram is shown with the
incubation conditions for each step.

Another BLItz sensogram indicating the correlation of the binding sites of the ligands
towards H69 is shown in Figure 5.6. This sensogram shows a binding event of H69 with
the two ligands differently from Figure 5.5. In Figure 5.6, Bi-UUU is immobilized to the
bionsensor prior to the ligands binding. At step 4, either neomycin or peptide TARHIY
was added, and in step 5, a different ligand was added. The data shown do not reveal a
Kd or total displacement that can show the binding sites overlap. However, the final
equilibrium response of the binding curves shows different levels when neomycin is
added relevant to the order of addition. When the peptide is added first followed by
addition of neomycin, the equilibrium response is lower compared to vice versa.
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3.12. Conclusions
In this chapter, phage display was done to find a peptide that has selective binding to
H69 ΨΨΨ at pH 5.5. The peptides selected did not reveal a preference for H69 ΨΨΨ
over UUU as hoped, but the peptide TPARHIY revealed a moderate preference for H69
over tRNAPhe. A truncated version, TARHIY was shown in the FID assay to have better
affinity for H69 than the selected peptide TPARHIY. Several binding studies were
performed, namely ESI-MS, BLItz, and NMR. Each study was performed at both pH 5.5
and pH 7.0 with H69 ΨΨΨ and H69 UUU. These studies revealed TARHIY binding to
H69, and gave the apparent Kd values. The peptide showed moderate binding affinity
(10-20 µM) with a Kd value close to that of a natural antibiotic, neomycin, binding to
H69.187 However, curve fits for Kd determination were poor and our results imply more
complex binding events than 1:1 interactions.
The binding site was examined by 2D NMR, which suggested binding near C1914 and
C1920. To the best of our knowledge, this is the first example of a small molecule
interacting with the loop region of H69 for the isolated RNA. All of the methods
complement each other, and the observed trends in Kd values were consistent. ESI-MS
and BLItz studies showed there was no apparent selectivity between H69 ΨΨΨ and H69
UUU.
Growth assays showed that the phage with TARHIY decrease E. coli amplification,
however, the difference from other sequences that are known fast growers was not
significant, leaving the possibility of the selected peptide being a fast grower with
moderate binding to the target. However, if complete growth inhibition is achieved, the
peptides would never be selected. Therefore, TARHIY may further be optimized to
enhance its binding affinity.
Peptide TARHIY exhibited moderate binding affinity with Kd values comparable to
those observed with neomycin binding to H69. Although selectivity was not achieved, the
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peptide could be used to screen for ligands binding to the H69 loop region with higher
affinity. In order to find a peptide selective for H69 ΨΨΨ, one may alter the selection
conditions. Specific elution may be useful, but, for a target with a flexible structure such
as H69, the resulting peptide may not be that selective. Another method that could be
useful for improving the peptide selectivity is counter-selection by performing biopanning
with H69 ΨΨΨ, followed by a secondary selection with H69 UUU or vice versa. Phage
expressing TPARHIY was obtained 38 times out of 105 sequences from round 3. This
sequence was dominant in the selection, suggesting that it is a fast grower, which was
supported by the growth assay results.
In this study, we used pH 5.5 buffer conditions, which was acidic compared to
physiological buffers commonly used in phage display. The yield obtained at each round
was significantly smaller (>10-fold) compared to selections from pH 7.0 conditions. Other
than the pH, we used biopanning conditions corresponding to previous studies.118 At
rounds 3 and 4, the incubation time was decreased from 2 to 0.5 h. Tight binders have
high koff values, which means the dissociation takes longer than weak binders. Therefore,
increasing the incubation time may help increase the affinity.
In this study, ESI-MS and SPR results suggested the possibility of 1:2 stoichiometry of
RNA:peptide binding. Also, NMR results showed binding at the loop region, which was
not seen previously with neomycin, and may imply a different binding mode than the
aminoglycosides. There is a possibility of multimeric binding, which leaves questions
regarding selection of monomer peptides from phage display. The binding mode of the
peptide to H69 was still not clear, which led to the following studies in Chapter 4, in
which multimeric binding of the peptides was explored.
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CHAPTER 4 – EXPLORING MULTIMERIC BINDING EFFECTS OF PEPTIDES
4.1. Design of branched peptides
In Chapter 3, peptide TPARHIY was selected from phage display, and a truncated
variant TARHIY exhibited moderate binding affinity for the desired target H69. As
mentioned in the previous section, a 2:1 binding stoichiometry of the peptide to H69 was
observed in ESI-MS studies, which led us to the design of a dimer peptide. Also, the
NMR spectra for H69 ΨΨΨ with TARHIY indicated two sites of H69 undergoing chemical
environment changes, namely C1914 in the loop, and C1920 in the stem near the loop.
An approximate distance between C1914 and C1920 using PyMOL is 2.5 nm, while the
monomer peptide length using Chem3D is 2 nm. Phage from the Ph.D.-7 library have
five copies of the peptide expressed on the pIII coat protein, leaving the possibility for
multimeric binding of the peptide to H69. Previous studies showed that branched
peptides could accommodate cell-penetrating ligands, thus increasing their potential
antibacterial activity.132, 189-190 Previous studies have also shown that peptides may bind
to their targets in a multimeric fashion,191 especially those identified from phage
display.190 These studies demonstrated that peptides found from phage display had
weaker binding affinity as a monomer compared to that of a multimer.132, 189, 191
Scatchard analysis on monomer binding was performed to determine whether
multimeric binding takes place (Figure 4.1). The binding ratio (Y) over peptide
concentration ([L]) was plotted against the binding ratio (Y) of the bound RNA over total
RNA concentration. For 1:1 binding mode, a linear plot is shown, which was not
observed with our ESI-MS data. Two linear slopes were observed, indicating two binding
modes. This could possibly explain the poor fitting for ESI-MS binding curves in Figure
3.14. Scatchard analysis revealed possible 2:1 binding or >1 binding mode of monomer.
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Figure 4.1. A Scatchard plot of H69 UUU binding to TARHIY is shown.

Based on this idea discussed above, we designed a dimeric peptide (Figure 4.2). The
peptide selected in Chapter 3 appeared 38 times out of 105 from sequencing analysis.
The binding affinity of the peptide to H69 was moderate (10-20 µM), with little selectivity
for modification status of H69. Our goal was to test if there is a multimeric binding effect
of the peptide. The phage has a Ser-Gly-Gly-Gly linker that is connected to the
randomized peptide on the N-terminus. In our study, we used β-Ala-β-Ala-β-Ala as a
linker, which provides the same number of carbons in between the monomer and the
branch, and one less amide group, allowing enhanced flexibility. A lysine residue was
used as the branch point, because of the ability to continue peptide synthesis off the side
chain.
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Figure 4.2. An image showing the rationale of the project and the structure of the
dimer peptide is given.
4.2. Synthesis of branched peptides
To synthesize a dimer peptide, lysine was selected as the branch point. Lysine has an
ε-amino group from the side chain, allowing addition of the same or different amino acids
onto each amino group by utilizing specific protecting groups on each amino group. For
this part of the study, Fmoc-Lys(Fmoc)-OH was used to add on identical peptide
sequences to the branch. Two sequences, TARHIY, the phage-selected sequence, and
AAAAAA, a control sequence, were the peptide monomers used to generate the dimer.
On the phage, there are three glycines and a serine at the C-terminus of the peptide
connected to the pIII coat protein, which works as a spacer.192 In this study, I added
three β-alanines (B), which are commonly used spacers (Scheme 4.1). Even with the
spacers after the branch, the surface of the resin was likely too crowded, leading to a
failed synthesis. After using a low-loading resin NovaSynTGR resin (0.31 mmol/g), I was
able to obtain the desired products in good yield and purity (Figure 4.3). The peptides,
(TARHIYBBB)2-K-NH2 (branched TARHIY, B1T) and (AAAAAABBB)2-K-NH2 (branched

91
AAAAAA, B1A), were generated by using standard Fmoc-solid phase peptide synthesis
(SPPS).132 The synthesized peptides were purified with HPLC and characterized by
MALDI-TOF MS.

Scheme 4.1. Synthesis of branched peptides with the same side chains
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Figure 4.3. MALDI-TOF spectrum (a) and HPLC trace (b) of B1T is shown.

Also, to examine whether the N-terminus of the peptide is important for activity (i.e.,
RNA binding), we designed branched TARHIY analogues. The sequences that were
designed are shown in Figure 4.4. For a) and b), Fmoc-Lys(Fmoc)-OH was used as the
branch point, and for c) and d), Fmoc-Lys(ivDde)-OH was employed. The protecting
group ivDde allowed attaching a different side chain (i.e., AAAAAABBB or YIHRATBBB)
onto the ε-amino group (Scheme 4.2). The peptides were synthesized with standard
Fmoc-solid phase peptide synthesis (SPPS) using NovaSynTGR resin, and three βalanines (B) were added as spacers. To determine the role of peptide monomer
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orientation, (TARHIYBBB)(YIHRATBBB)-K-prG-NH2 (reverse dimer TY) was designed.
Also, a propargylglycine (prG) was added on the C-terminus to facilitate further
modification on structures of the peptide, such as addition of a dye or small molecule for
further studies. For c) and d), the sequence TARHIYBBB was synthesized first with BocThr(Bzl)-OH on the ɑ-amino group, followed by ivDde deprotection with 5% hydrazine,
followed by Fmoc synthesis to add AAAAABBB or YIHRATBBB on the ε-amino group.
The synthesis was followed by purification by HPLC and characterization by MALDI-TOF
MS.

Figure 4.4. Structures of branched peptides with alkynyl groups are shown. The
following peptides were generated: a) (TARHIYBBB)2-K-prG-NH2 (dimer TT), b)
(TARHIYBBB)(AAAAAABBB)-K-prG-NH2 (dimer TA), c) (AAAAAABBB)2-K-prG-NH2
(dimer AA), and d) (TARHIYBBB)(YIHRATBBB)-K-prG-NH2 (reverse dimer TY).
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Scheme 4.2. Scheme of synthesis of branched peptides with different side chains

4.3. Binding of RNA with branched peptides using MALDI-TOF
To examine complex formation of branched peptides, binding studies with H69 were
carried out. The complex was detected by MALDI-TOF although this method is only
qualitative. To 2 μM of H69 in water was added 2 μM of peptide solution, and the mixture
was spotted on a MALDI plate using 3-hydroxypicolinic acid (HPA) as a matrix. The
branched peptides described above were tested, with both H69 ΨΨΨ and H69 UUU.
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Although not quantitative, this method does provide evidence for formation of complexes
with the dimer TT, dimer TA, and reverse dimer TY with H69 (Figure 4.5). Complexes
with the control dimer AA were not observed. Further studies were required to confirm
the binding.

Figure 4.5. MALDI-TOF results for binding of dimer TT, dimer AA, dimer TA, and
reverse dimer TY with H69 ΨΨΨ are shown. While complexes of dimer, dimer TA, and
reverse dimer TY with H69 were observed, complexes of dimer AA with H69 ΨΨΨ
were not detected by MALDI-TOF.
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4.4. Binding of RNA with branched peptides using ESI-MS
To determine the binding affinity of peptide (TARHIYBBB)2-K-NH2 (branched peptide,
B1T), ESI-MS was used. In this study, the binding was measured at 10 mM NH4OAc for
both pH 5.5 and pH 7.0 conditions, 1 μM of H69 ΨΨΨ and H69 UUU, and the
concentration of peptide varied from 0 to 100 μM. Unlike the monomer, there was no
overlap between the peptide and RNA peaks (Figures 4.6 to 4.9). In this case, intensity
of the (5-) charge state, which was highest, was used for quantification. In the previous
chapter in which monomers were examined, (5-) charge state was used. From the
apparent Kd values (Table 4.1) obtained from plots shown in Figure 4.10, it is found that
the binding affinities towards H69 ΨΨΨ and H69 UUU have both increased at least 10fold, but no apparent selectivity was observed.
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Figure 4.6. Representative ESI-MS results for B1T titration (pH 5.5) against H69 ΨΨΨ
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 5.5).
The expanded figures are displayed in Appendix E.
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Figure 4.7. Representative ESI-MS results for B1T titration (pH 5.5) against H69 UUU
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 5.5).
The expanded figures are displayed in Appendix E.
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Figure 4.8. Representative ESI-MS results for B1T titration (pH 7.0) against H69 ΨΨΨ
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 7.0).
The expanded figures are displayed in Appendix E.
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Figure 4.9. Representative ESI-MS results for B1T titration (pH 7.0) against H69 UUU
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 7.0).
The expanded figures are displayed in Appendix E.
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Figure 4.10. ESI-MS results for branched peptide B1T at 10 mM NH4OAc (pH 5.5 and
pH 7.0) against H69 ΨΨΨ and H69 UUU. a) The titration curves for TARHIY bound to
H69 ΨΨΨ and H69 UUU (y axis: binding ratio of at (5-) charge state) at different buffer
conditions (pH 5.5 vs. pH 7.0) are shown.

Table 4.1. Apparent dissociation constants (Kds) obtained from ESI-MS.

Scatchard analysis on dimer binding was performed (Figure 4.11). The binding ratio
(Y) over peptide concentration ([L]) was plotted against the binding ratio (Y) of the bound
RNA over total RNA concentration. For the monomer, two linear slopes were observed,
indicating two binding modes. Scatchard analysis revealed possible 2:1 binding or >1
binding mode of monomer. For the dimer, one linear slope was observed, which
indicates 1:1 binding mode.
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Figure 4.11. A Scatchard plot of H69 UUU binding to dimer peptide is shown.

4.5. Binding of RNA with branched peptides using BLItz
As a label-free method to monitor binding interactions, BLItz was used for dimer
studies. The dimer exhibited binding to H69, while the control dimer AA did not show
binding. For dimer TT, the apparent dissociation constant obtained was comparable to
that obtained by ESI-MS, which was 2.2 ± 0.1 μM for H69 ΨΨΨ and 3.9 ± 0.2 μM H69
UUU at pH 7.0. In contrast, SPR experiments were not successful with the dimer.
Apparent Kd values using steady state response units were obtained, but the
dissociation curves had very poor fits. Representative data are shown in Figures 4.12 to
4.14. By using BLItz, we were able to obtain the apparent Kd values for the fits. Dimer
peptide concentrations varying from 0 to 100 μM in buffers were studied.
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Figure 4.12. Representative BLItz results for branched peptide dimer TT titration at pH
5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and
H69 UUU. The curves shown in color correspond to measurements of a two-fold serial
dilution of the peptide ligands over a concentration range of 0 to 100 μM. The curves in
black correspond to global fits in 1:1 binding model. The experiments were performed
in triplicate. The expanded figures are displayed in Appendix B.
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Figure 4.13. Representative BLItz results for branched peptide dimer TA titration at pH
5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and
H69 UUU. The curves shown in color correspond to measurements of a two-fold serial
dilution of the peptide ligands over a concentration range of 0 to 100 μM. The curves in
black correspond to global fits in 1:1 binding model. The experiments were performed
in duplicate. The expanded figures are displayed in Appendix B.
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Figure 4.14. Representative BLItz results for branched peptide reverse dimer TY
titration at pH 5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0
(20 mM HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69
ΨΨΨ and H69 UUU. The curves shown in color correspond to measurements of a twofold serial dilution of the peptide ligands over a concentration range of 0 to 100 μM.
The curves in black correspond to global fits in 1:1 binding model (R2>0.98). The
experiments were performed in duplicated. The expanded figures are displayed in
Appendix B.
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Table 4.2. Rate constants (kon and koff) obtained from BLItz

Evaluation of the kinetics of the binding events revealed similar kon and koff values of
the dimers binding to H69 ΨΨΨ and H69 UUU at pH 5.5 and pH 7.0. The kon and koff
values are given in Table 4.2. For all of the dimers, compared to the monomer, ~10-fold
faster association and dissociation was observed. Dimer TT revealed ~100-fold faster
association to H69 and ~10-fold slower dissociation at pH 5.5 compared to the monomer.
If the binding interaction is through charge-charge interactions, it makes sense that the
association rate would be higher compared to the monomer due to increased charge on
the dimer. However, similar to the binding of TARHIY, poor fitting was observed, both for
the sensograms (Figures 4.10 to 4.12 and Appendix B) and the rate constants (Table
4.2), possibly implying the binding of TARHIY to H69 is not through 1:1 binding mode.
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Table 4.3. Apparent dissociation constants (Kds) obtained from BLItz

The apparent Kd value obtained for dimer TT binding to H69 was 2.5 ± 0.8 μM on
average, which is in agreement with that obtained from ESI-MS (2.9 ± 0.8 μM on
average). The apparent Kd value obtained with dimer TA was 13 ± 1 μM, which was
comparable to the value of TARHIY obtained with other methods (16 ± 5 μM with ESIMS and 15 ± 2 μM with BLItz). The apparent Kd value obtained for the reverse dimer TY
and H69 UUU was 36 ± 3 μM on average, which is 10-fold less than that of dimer TT,
and 3-fold lower than dimer TA or monomer peptide TARHIY towards H69 UUU. For the
dimer studies, dimer TA and reverse dimer were generated to see if the orientation of
the monomer units was important. The decrease in apparent Kd value obtained with
reverse dimer TY compared to dimer TT may indicate that the orientation of the peptide
is likely important, and also suggests multimeric binding.
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From previous Scatchard analysis of the ESI-MS results, the monomer exhibited 2
different slopes, while the dimer exhibited 1 slope. This result implied that the dimer may
go through a 1:1 binding mode with H69. Apparent dissociation constants obtained from
ESI-MS or BLItz both showed improved binding with dimer TT, suggesting the dimer TT
binds to H69 tighter than the monomer up to 10-fold. However, in the expanded BLItz
binding curves in Appendix B, dimer TT also does not show a good 1:1 fitting. This may
suggest that although 1 slope was obtained from Scatchard analysis for dimer TT, the
binding may not be through a 1:1 binding mode. Possibly adding more data points may
provide a better understanding of the data. Also, for the BLItz binding curves, for dimer
TT against H69 ΨΨΨ at pH 5.5, when the peptide concentration is lower than 6.3 μM,
the curves exhibited better fitting, while the curves did not exhibit decent fitting with H69
UUU or H69 ΨΨΨ at pH 7.0. Dimer TY also exhibited better fitting for both H69 and
buffer conditions at lower concentration, suggesting the peptide goes through a 1:1
binding. However, a better binding analysis may be required to understand the binding
mode. Also, molecular docking experiments may provide better understanding of the
binding mode as well.
4.6. NMR spectroscopy
In Chapter 3, binding of peptide TARHIY to H69 was examined by NMR. Small
changes in chemical shifts at C1914 and C1920 were observed in pH 5.5 buffer
conditions. In Sections 4.4 and 4.5, binding of these dimer analogues to H69 was
examined, and relative binding affinities were determined. In this section, binding of
dimer TT, dimer TA, and reverse dimer TY to H69 UUU (at pH 5.5 and pH 7.0) and H69
ΨΨΨ was examined by NMR, and ge-2D COSY was used to analyze JH5-H6 of the
pyrimidines. Peaks were assigned based on previously reported values.47, 166 Through
such studies, the binding site(s) of the peptides can be deduced. The samples were
prepared as mentioned in Chapter 2.8. The samples were then given to Evan Jones
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who obtained the NMR spectra on Bruker ADVANCE 700 MHz NMR (Billerica, MA)
equipped with a TXI cryoprobe at 298K.
Dimer TT binding to H69 was examined first since it is derived from two copies of the
parent monomer peptide. For H69 UUU at pH 5.5, chemical shift changes were
observed at C1909, C1914, U1917, C1920, and C1924, which suggests an overall
conformational change of the RNA, not just the loop region as we observed with the
monomer (Figure 4.15). For H69 ΨΨΨ at pH 5.5, the loop region was not resolved well,
however, we were able to observe a change at C1924 in the stem region (Figure 4.16).
This result was different from that obtained with the monomer, which showed a chemical
shift change at C1920. For H69 UUU at pH 7.0, changes at C1914 and C1920 were
observed, which was not observed with the monomer (Figure 4.17).

Figure 4.15. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of dimer TT at pH 5.5. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The arrow indicates the chemical shift change and
direction at C1914. The NMR spectra were obtained by Evan Jones.
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Figure 4.16. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or
presence (grey) of dimer TT at pH 5.5. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The arrow indicates the chemical shift change and
direction at C1914. The NMR spectra were obtained by Evan Jones.

Figure 4.17. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of dimer TT at pH 7.0. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The arrow indicates the chemical shift change and
direction at C1914. The NMR spectra were obtained by Evan Jones.
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Figure 4.18. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of dimer TA at pH 5.5. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The arrow indicates the chemical shift change and
direction at C1914. The NMR spectra were obtained by Evan Jones.

Figure 4.19. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or
presence (grey) of dimer TA at pH 5.5. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones.
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Figure 4.20. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of dimer TA at pH 7.0. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones.

Figure 4.21. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of reverse dimer TY at pH 5.5. The concentrations of RNA and
peptide were 50 and 500 μM, respectively. The arrow indicates the chemical shift
change and direction at C1914. The NMR spectra were obtained by Evan Jones.
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Figure 4.22. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or
presence (grey) of reverse dimer TY at pH 5.5. The concentrations of RNA and
peptide were 50 and 500 μM, respectively. The NMR spectra were obtained by Evan
Jones.

Figure 4.23. Overlay of the NMR spectra for H69 UUU in the absence (black) or
presence (grey) of dimer TA at pH 7.0. The concentrations of RNA and peptide were
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones.
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The dimer TT binding to H69 UUU exhibited different chemical shift patterns at pH 5.5
and pH 7.0. It has been reported previously that Ψ enhances base stacking, although the
global stabilities of H69 UUU and H69 ΨΨΨ are similar.185 Considering that all of the
dissociation constants are similar at both buffer conditions, this difference implies that
the binding modes of the peptides may differ. However, the overall change in H69 UUU
at pH 5.5 with dimer TT implies that the binding of the dimer TT compared to the
monomer may be more extensive, involving more contacts with the RNA. This result is
also consistent with the tighter affinity relative to monomer, as determined by ESI-MS
and BLItz.
Dimer TA binding to H69 was examined next to determine the role of the dimer identity.
For H69 UUU at pH 5.5, a small chemical shift change was observed at C1914 (0.02
ppm) and U1915 (0.01 ppm) upon addition of the peptide, which was similar to that of
the monomer (Figure 4.18). For H69 ΨΨΨ at pH 5.5, the loop region was not well
resolved, however, we were able to observe a slight (0.01 ppm) chemical shift change at
U1923, which is in the stem region (Figure 4.19). This was different from the result
obtained with the monomer, which only showed a chemical shift change at C1920. For
H69 UUU at pH 7.0, no change was observed, which was similar to the result with the
monomer (Figure 4.20). Similarity of the binding affinities of dimer TA and monomer
binding to H69 were observed in previous ESI-MS and BLItz studies as well, implying
the branch moiety (AAAAAA) does not impact the interactions with the RNA.
Reverse dimer TY binding to H69 was examined to determine whether the sequence
orientation was important. For H69 UUU at pH 5.5, a chemical shift upfield was observed
at C1914 (0.02 ppm), which was in a different direction from the monomer or dimer TT
changes (Figure 4.21). This shows that the orientation of the peptide is important in the
peptide binding to H69. For H69 ΨΨΨ at pH 5.5 (Figure 4.22) or H69 UUU at pH 7.0
(Figure 4.23), no change was observed.
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In Sections 4.4 and 4.5, binding studies have shown that in comparison to the
monomer, affinity of dimer TT increased up to 10-fold, but the dimer TA was similar, and
the reverse dimer TY had 3-fold lower binding. Although the binding affinities of the
monomer to H69 under different buffer conditions were similar, the NMR studies have
shown that H69 ΨΨΨ at pH 5.5 or H69 UUU at pH 7.0 spectra had little or no changes in
the chemical shifts upon peptide binding. Previous NMR studies revealed that for H69
ΨΨΨ, local base-stacking interactions exist with Ψ1911-A1919-A1918-Ψ1917-A1916Ψ1915, while in H69 UUU only A1916 and U1917 participate in base stacking. 48,

166

These results also agreed well with DMS probing and SHAPE analysis.178, 193 For H69
ΨΨΨ, Ψ modifications were shown to enhance base stacking, yet through the
modifications the global structure is altered compared to the unmodified RNA, which is
overall thermodynamically destabilizing due to constraints on the loop structure.185

Figure 4.24. A schematic description of residues of H69 that showed a change upon
peptide binding are marked.

Upon binding of dimer TT, both H69 ΨΨΨ and H69 UUU have shown changes in
chemical shifts for C1914 and Ψ/U1915, which implies binding to the loop region. Also,
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for both H69 ΨΨΨ and H69 UUU at pH 5.5, change at C1920, and C1924 were
observed, which may imply that there is a change in the overall conformation upon
binding. The differences between H69 ΨΨΨ and H69 UUU in binding to the dimer TT
were the additional changes in chemical shift observed in H69 UUU. However, residues
in the loop region of H69 ΨΨΨ did not resolve well (C1914 and Ψ1915), possibly due to
the flexible structure on the 5'-side of the loop. Residue Ψ1917 was shown to have an
interaction with A1912, which protects that residue from solvent exposure.185 At pH 5.5,
the stem-closing base pairing of Ψ/U1911 and C1920 was shown to be destabilized for
both H69 ΨΨΨ and H69 UUU.166 In contrast, H69 UUU displayed a continuous basestacking interaction at U1911-A1912-C1914-U1915. With H69 at pH 7.0, the dimer TT
showed interaction to the loop residues C1914 and U1915. Although the binding studies
with ESI-MS and BLItz have shown the binding affinities to be similar to each other, the
binding patterns in NMR studies were different. It is possible that the relaxed structure of
H69 UUU at pH 7.0 plays a role in the different binding interactions with the peptides.
4.7. Conclusions
Multivalent effects of the peptide were explored by synthesizing dimer TARHIY and
derivatives. By designing a dimeric peptide utilizing lysine as a branching point and βalanine as a linker, we were able to synthesize a dimeric peptide. Binding studies with
ESI-MS and BLItz showed that the dimer TT peptide has enhanced binding compared to
the monomer, which was also shown through Scatchard analysis. The peptide dimer
derivatives with AAAAAA exhibited similar binding to the monomer. Reverse dimer TY
with reverse sequence YIHRAT instead of TARHIY showed decreased binding. Studies
with reverse dimer TY support the idea that there may be multivalent binding of the
peptide to H69 as well as the importance of the orientation of the peptide. However,
there is room for improvement for the design of the peptides. The branching point and
linkers do not exactly match the original design of the phage library, which raise some
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questions on the dimeric peptide studies. The linker can also be modified by using
PEGylated linkers, which would add more flexibility to the peptides, and also will be
resistant to degradation.
One important fact we learned from BLItz studies was that the binding of the dimer TT
to H69 was ~100-fold faster in association and ~10-fold faster in dissociation compared
to the monomer TARHIY. The binding mode of TARHIY to H69 was not very clear from
Chapter 3. With the increase of charge with the dimeric structure, the faster
association/dissociation may support the binding to be through charge-charge
interactions. Although the dimer TT and reverse dimer TY have the same amino acid
composition, the orientation of the charges make a difference in both binding affinity and
rate constants, also supporting the importance of orientation. The data obtained with
ESI-MS or BLItz studies showed poor fitting, which suggests the peptide interaction to
H69 may not be through a simple 1:1 binding or conditions for the experiments may
need optimization.
The NMR spectra obtained with NMR have shown changes in the chemical shifts for
the stem region residues, which indicate an overall conformation change of the RNA
upon peptide binding (Figure 4.23). In the NMR studies, the orientation of the peptide
was important for the dimeric peptide binding. Overall, the work in this chapter has
revealed the importance of the orientation of peptide binding to H69, along with the
multimeric binding.
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Figure 4.25. A schematic figure of dimer TT and reverse dimer is shown.
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CHAPTER 5 – Future directions and Summary
5.1. Future directions
5.1.1. Optimization of the branched peptide binding
In Chapter 4, dimeric peptides were synthesized, and binding studies revealed
enhanced binding of those peptides compared to the monomer. However, the design of
the peptide can be improved by optimization of the structure. We used lysine as a
branching point, which was also used in previous studies involving multimeric peptide
syntheses.132, 189 However, these studies can only explore dimeric binding, while studies
from Bastings et al. have shown studies with multimers including dimers, teteramers,
and pentamers.
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In their study, the dendrimeric branch was synthesized, followed by

attaching the peptide of interest via native chemical ligation (NCL). Dendrimeric
branches will help explore multimeric binding. Also, by adding a clickable moiety such as
an azide or alkyne, along with multimers, other molecules can be attached to the peptide
(i.e., fluorescent dyes or potent molecules with binding affinity or cell-penetrating activity).
Also, the distance between the branch and peptide can be optimized. In our study, βalanine was incorporated as a linker. However, previous studies have used different
linkers in between, such as polyethyleneglycol (PEG), aminohexanoic acid (Ahx), βalanine (β-Ala), or 2-(2-aminoethoxy)ethoxy (AEEAc).132,

189-190

Also, in the study by

Hooks et al., methionine, lysine, and D-lysine were used as spacers that can avoid
aggregation of the peptide sequences.132 Optimization of the linker length along with
chemical properties may enhance binding affinity to H69. In order to find an optimal
distance, PEGylated amino acids can be incorporated as linkers, with structures shown
in Figure 5.1. Also, by changing the linker length between the branching point and
TARHIY, the optimal linker length can be found, by adding PEG groups as spacers.194-195
Addition of PEG or propargylglycine onto either C- or N-terminus will allow observation
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of the effect of the functional groups on each terminus. Synthesis of TARHIY peptides
with PEG linkers was completed.

Figure 5.1. Structure of TARHIY peptides with PEG spacers is shown. The
propargylglycines and PEG groups were added to either the N-terminus or the Cterminus.

5.1.2. Developing TARHIY as a probe for H69 loop region binding studies
In Chapter 3, TARHIY exhibited binding for H69 in the loop region. This was not seen
previously, which may lead to the development of a probe targeting the loop region of
H69. Also, dimer TT exhibited enhanced binding to H69. The binding sites of dimer TT
was determined by NMR in Chapter 4. Dimer TT was shown to primarily bind to the loop
region with H69 UUU at pH 7.0 and H69 ΨΨΨ at pH 5.5, and to change the overall
chemical shifts with H69 UUU at pH 5.5. Previous studies have shown that RRF
interacts with H69 in the loop region, which then reduces H69 interactions important for
the B2a intersubunit bridge of the 70S ribosome.32, 61, 186, 188 Aminoglycosides primarily
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bind to H69 in the stem region, and the overall conformation changes upon binding. The
interaction between H69 and RRF was shown to be disrupted upon binding of
aminoglycosides, leading to inhibition of ribosome recycling.186 In this thesis work,
peptide TARHIY was shown to bind to the loop region with moderate affinity. Attaching
fluorescent labels to the peptide TARHIY or dimer TT will enable screening molecules
binding to H69 in the loop region. Also, fluorescence resonance energy transfer (FRET)
assays may be employed to monitor changes in H69 and RRF interactions upon
molecule binding.
5.1.3. Mapping of H69 with TARHIY analogues using ESI-MS
A 29-nucleotide hairpin structured RNA, trans-activating response element (TAR) RNA
(5′-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3′), is found in 5'-end of nascent
HIV-1 transcripts, which has an extinction coefficient of 268,900 L/mol•cm. 195 Transactivating (Tat) protein (H2N-GRKKRRQRRRPP-NH2) is an arginine-rich motif, which
has tight binding to TAR RNA, reported to bind to the bulge and loop region.195 The
binding affinity is 0.7 µM, and this is a well-established system for RNA-protein binding
studies.195 Rana et al. have selected heterochiral tripeptides binding to the bulge region
using TAR lacking the bulge as a competitor using one-bead-one-compound (OBOC)
assay.196 The tripeptide KkN exhibited tighter binding than Tat protein (0.4 µM), and Rkv
exhibited weaker binding (10 µM).196 To find the binding region at the molecular level,
ESI-MS mapping would be ideal. Among other biophysical methods used in this study,
only NMR spectroscopy and ESI-MS only can monitor ligand binding sites on RNA at a
molecular level. While NMR spectroscopy has a limitation of requiring a large amounts of
the sample, ESI-MS only requires small amount of sample. In our NMR studies, although
the binding affinities appeared to be similar, H69 ΨΨΨ and H69 UUU showed different
patterns for binding dimer peptides. Furthermore, some peaks were difficult to observe
due to the flexible nature of the H69 loop region. ESI-MS mapping may allow monitoring
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of these flexible regions upon binding to peptides. Since the binding region is known for
TAR RNA to Tat peptide, employing ESI-MS and establishing mapping methods with the
tripeptides (KkN and Rkv) would be valuable. This approach could be used to detect
binding regions of other peptides to target RNAs, such as H69. We could monitor
binding of TARHIY or neomycin towards modified or unmodified variants of H69.197
Currently, the mapping studies using ESI-MS are being done in the Rodgers’ lab. TAR
RNA was prepared using T7 polymerase in vitro transcription, and the peptides were
prepared using solid-phase peptide synthesis.

Figure 5.2. Structures of TAR RNA and H69 UUU and peptides that can be employed
for mapping studies are shown.

5.2. Summary
In order to find a ligand that can target H69 of the bacterial ribosome, in Chapter 3,
phage display was performed in pH 5.5, and several peptides were selected. The
selected peptides were synthesized, and a peptide TARHIY was selected by FID assay
for further binding studies. The peptide TARHIY showed moderate binding to H69
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employing ESI-MS and BLItz. However, the selected peptide TARHIY did not show
selectivity towards a certain conformation or type of H69, although the peptide showed
selectivity towards H69 over tRNAPhe. The binding site of peptide TARHIY was
determined to be in the loop region of H69 employing NMR, which was not observed
previously.
In Chapter 4, analogues of dimers were synthesized and the binding of those to H69
were studied. These studies have shown that the peptide TARHIY may be binding to
H69 in a cooperative manner, shown in increased binding affinity with ESI-MS and BLItz,
and change in conformation with a dimer that was monitored with NMR. Also, The dimer
exhibited improved binding comparable to the binding affinity of neomycin. Based on our
NMR studies, H69 UUU showed conformational changes upon dimeric binding, which
were similar to that of neomycin binding to H69.
In Chapter 5, dual binding of neomycin and peptide TARHIY were examined with
MALDI-TOF and BLItz studies. Neomycin, a well-known aminoglycoside binds to H69 at
the stem region. It was shown that there is a complex of neomycin, peptide TARHIY, and
H69. However, although the primary binding sites have been shown to be different for
the two ligands, when they are incubated together with H69, the binding events may not
be independent from each other. Previous studies of Agris et al.187 have shown that
neomycin may bind to H69 in a cooperative manner by changing the conformation of
H69. The BLItz experiment has shown that the binding of neomycin and peptide TARHIY
may not be independently binding to H69. This may imply although the primary binding
sites are different, neomycin and peptide TARHIY may bind to H69 in a similar fashion
by altering the conformation.
Overall, a peptide sequence targeting H69 was identified from phage display, and
using various methods, the peptide exhibited moderate binding. The peptide showed
binding to the loop region of H69, which was not observed previously. A known
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aminoglycoside neomycin binds to the stem region of H69, therefore, dual binding was
explored by monitoring a complex formation with MALDI-TOF. Serial incubation then left
dual binding of neomycin or peptide TARHIY to be questionable. Also, multimeric
binding was observed with the peptide TARHIY, which was then studied with dimeric
peptides, which showed enhanced binding. This result indicates that peptides selected
using phage display may be useful parent sequences, however, whether the monomer is
a tight binder itself or multimeric effects enhance the binding need to be considered.
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Figure A7. MALDI-TOF spectrum (a) and HPLC trace (b) of SILPYPY is shown.
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Figure B1. Representative BLItz results for TARHIY titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent
the 1:1 fitting curve.
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Figure B2. Representative BLItz results for TARHIY titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent
the 1:1 fitting curve.
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Figure B3. Representative BLItz results for TARHIY titration at pH 7.0 (20 mM HEPESKOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines
represent the 1:1 fitting curve.
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Figure B4. Representative BLItz results for TARHIY titration at pH 7.0 (20 mM HEPESKOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black lines
represent the 1:1 fitting curve.
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Figure B5. Representative BLItz results for dimer TT titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent
the 1:1 fitting curve.
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Figure B6. Representative BLItz results for dimer TT titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent
the 1:1 fitting curve.
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Figure B7. Representative BLItz results for dimer TT titration at pH 7.0 (20 mM HEPESKOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines
represent the 1:1 fitting curve.
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Figure B8. Representative BLItz results for dimer TT titration at pH 7.0 (20 mM HEPESKOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black lines
represent the 1:1 fitting curve.
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Figure B9. Representative BLItz results for dimer TA titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent
the 1:1 fitting curve.

152

Figure B10. Representative BLItz results for dimer TA titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent
the 1:1 fitting curve.
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Figure B11. Representative BLItz results for dimer TA titration at pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black
lines represent the 1:1 fitting curve.
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Figure B12. Representative BLItz results for dimer TA titration at pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black
lines represent the 1:1 fitting curve.
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Figure B13. Representative BLItz results for dimer TY titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent
the 1:1 fitting curve.
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Figure B14. Representative BLItz results for dimer TY titration at pH 5.5 (20 mM
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent
the 1:1 fitting curve.
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Figure B15. Representative BLItz results for dimer TY titration at pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black
lines represent the 1:1 fitting curve.
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Figure B16. Representative BLItz results for dimer TY titration at pH 7.0 (20 mM
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black
lines represent the 1:1 fitting curve.
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APPENDIX C. CHEMICAL SHIFT CHANGES OF H69 UPON PEPTIDE TITRATION
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APPENDIX D. BUFFERS USED IN THIS THESIS STUDY
Buffer A
20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1 mg/mL BSA
with 0.1% (v/v) Tween-20
Buffer B
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v)
Tween-20 (buffer B)
Binding buffer (pH 7.0)
20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1 mg/mL BSA
Binding buffer (pH 5.5)
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v)
ESI-MS buffer (pH 5.5 or pH 7.0)
10 mM NH4OAc, 50% isopropanol
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Figure E1. Expanded view of representative ESI-MS results for TARHIY titration (pH
5.5) against H69 ΨΨΨ.
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Figure E2. Expanded view of representative ESI-MS results for TARHIY titration (pH
5.5) against H69 UUU.
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Figure E3. Expanded view of representative ESI-MS results for TARHIY titration (pH
7.0) against H69 ΨΨΨ.
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Figure E4. Expanded view of representative ESI-MS results for TARHIY titration (pH
7.0) against H69 UUU.
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Figure E5. Expanded view of representative ESI-MS results for B1T titration (pH 5.5)
against H69 ΨΨΨ.
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Figure E6. Expanded view of representative ESI-MS results for B1T titration (pH 5.5)
against H69 UUU.
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Figure E7. Expanded view of representative ESI-MS results for B1T titration (pH 7.0)
against H69 ΨΨΨ.
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Figure E8. Expanded view of representative ESI-MS results for B1T titration (pH 7.0)
against H69 UUU.
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In the development of methods to peptides targeting helix 69 (H69) of 23S ribosomal
RNA (rRNA) in bacterial ribosomes, phage display was employed at pH 5.5, a buffer
condition previously reported to favor H69 in a closed conformation. After sequencing
the selected phage, several peptides were chosen through sequence alignments,
followed by preparation using solid phase peptide synthesis. The peptides were
characterized by using matrix assisted laser desorption/ionization-time of flight (MALDITOF) mass spectrometry and purified by high performance liquid chromatography
(HPLC). A truncated peptide TARHIY was selected from fluorescence dye displacement
(FID) assay. Through binding studies using electrospray ionization mass spectrometry
(ESI-MS), surface plasmon resonance (SPR), biolayer interferometry (BLItz), and
nuclear magnetic resonance (NMR), the binding of the peptide to H69 was quantified,
and the, stoichiometries and interaction sites were determined. The peptide exhibited
moderate binding affinity towards H69 (apparent Kd~10 µM) using ESI-MS, SPR, and
BLItz, and the results from the various methods matched well. However, no differences
in H69 affinities were observed under different buffer conditions and the RNA type (i.e.,
modified or unmodified) was not distinguished by the peptide. Data obtained from ESIMS suggested dimeric binding at higher concentrations, which was explored in the later
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part of the research. The interaction site of the peptide towards H69 was explored using
NMR, which indicated binding to the loop region of H69, which was not observed before.
Although the desired selectivity towards H69 ΨΨΨ was not obtained, the selected
peptide TARHIY exhibited moderate binding to H69 that can further be developed as a
probe for H69 loop region.
Multimeric binding of peptides to H69 was explored by using dimeric peptides. Dimeric
peptides with the same or different sequences on amino groups of lysine were prepared
using solid phase peptide synthesis. Improved binding affinities (apparent Kd~1 µM) of
the dimer towards H69 (modified and unmodified variants) compared to the monomer
peptide were observed by ESI-MS and BLItz. The binding affinity of the dimer TT was
comparable to neomycin, a known aminoglycoside, while reverse dimer TY, exhibited
decrease in binding affinity, suggesting the N-terminus plays an important role in binding,
and that the 1:2 RNA:peptide complexes observed in ESI-MS spectra were not solely
due to aggregation. An overall conformational change was observed with dimer TT using
NMR, which was also comparable to neomycin. Further studies will help elucidate the
actual binding mode of peptide TARHIY towards H69. These results suggest the
possibility of multimeric binding should be taken into consideration with peptides
selected from phage display.
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